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Abstract:  
The aim of this study is to highlight and identify osteoporosis in the elderly as well as to 
analyze on the current risk factors causing osteoporosis and pharmacological prevention 
and treatment. This study has three research questions, question one is: What are the current 
risk factors that cause osteoporosis in the elderly and can they be changed? Question two: 
What are the classifications of osteoporosis medications and their effects on the disease? 
And question three is: What are the current approved medications for osteoporosis and their 
methods of administration? Studies used in the literature review of this thesis included 
elderly people from all races.The method chosen was literature review. Previous researched 
articles of relevance to effectiveness, acceptability and ethical issues were sought. It can be 
concluded that osteoporosis prevention requires adequate calcium and vitamin D intake, 
regular physical activity, and avoiding smoking and excessive alcohol ingestion, intake of 
proper nutrition and living a healthy life style. Risk of fracture determines whether medica-
tion is also warranted. A previous vertebral or hip fracture is the most important predictor 
of fracture risk. Bone density is the best predictor of fracture risk. Age, weight, certain me-
dications, and family history also help establish a person's risk for osteoporotic fractures. 
All women should have a bone density test by the age of 65 or younger (at the time of me-
nopause) if risk factors are present. Guidelines for men are currently in development. Medi-
cations include both antiresorptive and anabolic types. Antiresorptive medications estro-
gens, selective estrogen receptor modulators (raloxifene), bisphosphonates (alendronate, 
risedronate, and ibandronate) and calcitonins work by reducing rates of bone remodeling. 
Teriparatide (parathyroid hormone) is the only anabolic agent currently approved for osteo-
porosis in the United States. It stimulates new bone formation, repairing architectural de-
fects and improving bone density. All persons who have had osteoporotic vertebral or hip 
fractures and those with a bone mineral density diagnostic of osteoporosis should receive 
treatment. In those with a bone mineral density above the osteoporosis range, treatment may 
be indicated depending on the number and severity of other risk factors. 
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1. INTRODUCTION 
Osteoporosis is a disease characterized by low bone mineral density and structural dete-
rioration of bone tissue leading to bone fragility and increased cases of fractures particu-
larly of the hip, spine and wrist. 
 Osteoporosis results from reduced bone mineral density. It has enormous impact on 
public health and on the quality of life of the elderly (Goltzman David 2008). Osteopo-
rosis is one of the major cases of disability, morbidity and mortality in older people. It is 
a current world wide socioeconomic problem with an increasing severity and frequency 
due to the progressive aging of the world‟s population. The health of the bones depends 
on the genes, the level and hormones in the body, how physically active the body is and 
what an individual eat. There are also other factors that cause the decrease of bone den-
sity causing osteoporosis. Some of the causes can be controlled while others cannot be 
controlled 
 
Osteoporosis is a disease in which the bones become weak and more likely to break. 
People with osteoporosis most often break bones in the hip, spine and wrist. This 
condition can cause pain, difficulty in breathing, a loss of independence and even death 
when complications occur from some fractures. Breaking of bones can be caused from 
minor falls or in serious cases from simple action such as sneeze or bumping into 
furniture (National Osteoporosis Foundation)  
 
Osteoporosis is a chronic progressive disease of multi factorial. It is the most common 
metabolic bone disease in the United States. It has been most frequently recognized in 
elderly white women, although it does occur in men and women, all races, and all age 
groups. This disease is considered a "silent thief" that generally does not become 
clinically apparent until a fracture occurs. Screening at-risk populations is therefore 
essential (Kosmin, 2011)  
10 
 
As one age, bone mass tend to decline due to a variety of factors. Osteoporosis or osteo-
penia which is an early warning sign, signals an imbalance in the remodelling signal. 
Too much bone is broken down and too little new bone is built back this result to brittle 
bones which are prone to fracture. A combination of causes is often to blame for bone 
loss (Buffum, 2011) 
 
The body is constantly at work breaking down and rebuilding the bones. Specialized 
bones called osteoblast pull calcium, magnesium and phosphorous from the blood to 
build bone mass. Usually the body does not show any symptoms of osteoporosis until a 
fracture occurs or a vertebra collapses causing a loss of height and a hump in the back. 
. 
1.1 Statistics  
Osteoporosis is a recognized major public health problem in both developed and devel-
oping countries. As the age span has increased, osteoporosis has become the fourth most 
common disease in aged adults. Due to the high degree of morbidity and mortality asso-
ciated with fracture, prevention of such events is imperative because the number of 
women at risk for osteoporosis is expected to rise dramatically with the aging world 
population.  It has been estimated that the total medical care costs for osteoporosis in 
Europe including hospitalization and rehabilitation were 36.3 billion Euros in 2000 and 
the corresponding projected costs in 2050 will be 76.8 billion Euros, this is more than 
double. Worldwide projections estimate the number of hip fractures by 2050 could 
range between 7.3 and 21.3 million with a corresponding cost of 100 billion Euros. 
(Dontas, 2007) 
 
From many studies, it is clear that there are several risk factors that cause osteoporosis. 
Statistics shows that there are 75 million people in Europe, USA, and Japan that are af-
fected by osteoporosis. For the year 2002, there were estimated 9 million new osteopo-
rotic fractures of which 1.6 million were at the hip, 1.7 million were at the fore arm and 
1.4 million were clinical vertebral fractures. Europe and America accounted for 5.1 per-
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cent of all these fractures (International Osteoporosis Foundation). In the year 2002, 
there were estimated almost 44 million women and men in the states with either osteo-
porosis or low bone mass which is a condition of thinning bones that increases an indi-
vidual risk for developing osteoporosis. In New York State alone, 3 million men and 
women have osteoporosis or low bone mass. In the United States nearly one of every 
two Caucasian or Asian women over fifty will experience a fracture as a consequence of 
osteoporosis. Men and women of other ethnic groups have a slightly lower but still sub-
stantial risk for fracture. While it is typical to lose some bone mass as one age, it is not a 
normal thing to develop osteoporosis, to experience painful fractures or to lose more 
than one to a half inches of height. (Hayes, 2003)  
 
As the global population ages, the prevalence of age related osteoporosis this is postme-
nopausal osteoporosis, male osteoporosis and related fractures is likely to increase con-
siderably. In the US, the prevalence of osteoporosis is expected to grow from an esti-
mated 10 million in 2002 to 14 million by 2020. In the EU, the total number of hip frac-
tures is estimated to increase from 414 000 to 972 000 from year 2000 to 2050 ((Na-
tional Osteoporosis Foundation 2005) 
Vertebral fractures are estimated to increase during this time from 23.7 million to 37.3 
million. The economic consequences of osteoporosis with its associated morbidity and 
mortality due to fractures are staggering. While total world-wide estimates are not readi-
ly available, there are data that describe the costs in various countries. In Belgium (pop-
ulation ~10 million), the total cost of hip fractures in 1996 was almost 126.2 million U.S 
dollars per year (Reginster et al 1999). The estimated cost of osteoporotic fractures in 
females greater than 50 years of age using 1997 figures cost the UK 727 million pounds  
and 1.23 billion U S dollars or an estimated 942 million 1.6 billion U S dollars includ-
ing men, assuming the cost of treatment was the same as females. The annual cost of 
osteoporotic fractures to the US healthcare system in 2001 was approximately17 billion 
U.S dollars, with a single hip fracture costing approximately 40 000 U.S dollars (Na-
tional Osteoporosis Foundation 2004). 
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In Kenya prevalence of osteoporosis in post-menopausal women is about 24.3 per cent 
as compared to 0.9 per cent in pre-menopausal women. Prevalence of osteopenia is re-
ported to be 32 per cent and 20.5 per cent in post and pre-menopausal women respec-
tively. (Odawa , Ojwang , Muia , et al,  2004) 
 
More women die from osteoporosis related fractures than from breast cancer, cervix and 
uterus cancer combined. Osteoporotic fractures are the cause of 200,000 deaths annually 
in the U.S which is about one tenth of all deaths. Health cost in 2002 for osteoporotic 
fractures alone was 18 billion dollars (Karmen, 2011) 
 
Since this is an alarming issue in the society today. The most logical thing the world 
should do is trying and prevents the bone from losing its density. In order to know how 
to do that, one must be able to identify or detect the risk factors that cause osteoporosis 
 
Osteoporosis has been shown in the studies to have large genetic components. A paren-
tal history of fracture confers an increased risk of fracture that is independent of bone 
mass density (International Osteoporosis Foundation). Major factors include low body 
mass index, female sex, older age, family history of hip fracture, patient history of fra-
gility fracture, use of steroids, auto immune disease, secondary causes of osteoporosis, 
smoking, more than three alcoholic drinks a day and low bone mass in the hip region 
(Karis 2005). Many people with osteoporosis have several risk factors but others who 
develop have no known risk factors. There are some risk factors which can be changed 
while others cannot be changed (e med TV 2006)  
 
Calcium is essential for maintaining the health of the bones but cannot guarantee the 
health of the bones completely. Many studies show that certain foods are more effective 
than the pill supplements to maintain bone density. 
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Eating a well balanced diet rich in calcium and getting adequate vitamin D, engaging in 
regular exercise and making healthy lifestyles choices will promote healthy bones 
(Hayes 2003). Individuals that exercise regularly, expose themselves to healthy amount 
of sunshine and eat a whole foods diet based around dark green leafy vegetables, fruits, 
beans, nuts, seeds and lean sources of proteins are taking the right steps towards osteo-
porosis prevention (Hottinger Greg).  The role ethnicity plays in the incidence and pre-
valence of osteoporosis is connected to genetics and is also integral to other risk factors, 
such as nutrition and physical activity. 
 
2.  AIMS AND RESEARCH QUESTIONS 
 
The significance of this study is to discuss osteoporosis disease in the elderly (65+), and 
to identify and review pharmacological and non pharmacological prevention and treat-
ments. This paper also provides important information about the adverse effect of sev-
eral factors on the bone health and which factors can be changed and which cannot be 
changed. This paper also attempt to explain how osteoporosis medications that are ap-
proved by the Food and Drug Administration (FDA) are classified in categories accord-
ing to their different purposes on the disease and also oh how they should be adminis-
tered to patients. 
 
2.1 Research questions 
1. What are the current risk factors that cause osteoporosis in the elderly and can they be 
changed? 
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2. What are the current approved osteoporosis medications and how they have been 
classified according to their purpose? 
3. What are the methods of administration for these medications?  
3. THEORETICAL BACKGROUND 
 
This Chapter explores the various medical contents of previous researches on the inde-
pendent variables present in this study. From this chapter, we get a clear understanding 
of bone cells, bone remodeling processes and how deterioration of bone mineral density 
leads to osteoporosis from a medical perspective. This chapter also explains the differ-
ent levels of osteoporosis and some of the theories about osteoporosis 
In the 1930s, osteoporosis became an object of clinical engagement to the American 
physician Fuller Albright during his study in Germany. In the 1940s, Albright imported 
his interest in osteoporosis from Germany to United States (Nordin Christopher 2004) 
 
In the medical literature, osteoporosis is currently presented as a major global public 
health problem, one that has already been proposed as the disease of the twenty-first 
century (Clark 2002). As a consequence of its current medical definition, approximately 
200 million women worldwide are described as having osteoporosis   In modern 
medicine, osteoporosis is understood as a skeletal disorder characterized by decreased 
bone mass, leading to an increased risk for fracture of the hip, spine, wrist, and other 
skeletal sites (Lane 2006).   
Not only has osteoporosis been attributed an important role in the causation of fractures 
but it is also seen as a major killer. This is because hip fractures are perceived as 
causing what in medical terms is described as an excess mortality among the aged. With 
an increasing longevity in the world population (Cummings and Melton 2002), Proper 
understanding of the morphological degeneration in osteoporosis requires knowledge of 
the remodeling processes. These processes are conducted by specialized bone-resorbing 
cells (osteoclasts) and bone-forming cells (osteoblast). (Ruimerman Ronald 2005)  
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The modeling and remodeling processes are not very different at the cellular level. They 
are based on the separate actions of bone resorbing cells called osteoclasts and bone 
forming cells called osteoblasts. The remodeling process begins at a quiescent bone 
surface with the appearance of osteoclasts. These are large multinucleated cells that 
form by fusion of mononuclear precursors of haemotopoetic origin (Ruimerman Ronald 
2005) 
Osteoclasts are large multinucleate cells this are cells with more than one nucleus that 
differentiate from another type of cell called a macrophage. In normal bone, bone 
formation and bone resorption are closely coupled processes involved in the normal 
remodeling of bone. In osteoporosis, the net rate of bone resorption exceeds the rate of 
bone formation, resulting in a decrease in bone mass without a defect in bone 
mineralization.  
In women, osteoclast activity is increased because of decreased estrogen after 
the menopause. Men with prematurely decreased testosterone may also have increased 
osteoclast activity. These changes result in further net loss of bone. The amount of bone 
available for mechanical support of the skeleton eventually falls below 
the fracture threshold and one may suffer a fracture with little or no trauma. 
(http://www.medterms.com/script/main/art.asp?articlekey=11794) 
Osteoclasts are a type of bone cell that removes bone tissue by removing its mineralized 
matrix and breaking up the organic bone (organic dry weight is 90% collagen). This 
process is known as bone resorption. Osteoclasts were discovered by Kolliker in 1873. 
They are active mostly on the surface of cancellous bone or the spongy tissue and in 
cortical bone.  Osteoblasts are the cells that create the bone tissue that lay down the 
minerals. The resorption/removal process is faster than the laying down of new bone by 
osteoblasts, so an increase in bone formation and remodeling overall results in a loss of 
bone mass, when it occurs in adults. Glucocorticoid drug use and other physiological 
conditions such as chronic inflammatory disorders and thyroid hormone problems can 
contribute to the risk of bone fracture. (Latina Health Projec 2009-2011) 
Osteoblasts are bone cells that make bone. It does so by producing a matrix that then 
becomes mineralized. Bone mass is maintained by a balance between the activity of os-
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teoblasts that form bone and other cells called osteoclasts that break it down (Medicine 
Net.com).   
 
Osteoporosis can affect almost the entire skeleton. It is a systemic skeletal disease cha-
racterized by low bone mass and micro architectural deterioration of bone tissue, with a 
consequent increase in bone fragility. The disease often does not become clinically ap-
parent until a fracture occurs. Osteoporosis represents an increasingly serious problem 
in the United States and around the world. Many individuals, male and female, expe-
rience pain, disability, and diminished quality of life as a result of having this condition. 
The economic burden the disease imposes is already considerable and will only grow as 
the population ages (Kosmin Dana Jacobs 2011) 
 Despite the adverse effects of osteoporosis, it is a condition that is often overlooked and 
under treated in large part because it is so often clinically silent before manifesting in 
the form of fracture.   
A Gallup survey performed by the National Osteoporosis Foundation revealed that 75 
per cent of all women aged 45-75 years have never discussed osteoporosis with their 
physicians. Failure to identify at-risk patients, to educate them, and to implement pre-
ventive measures may lead to tragic consequences. It is a preventable disease that can 
result in devastating physical, psychosocial, and economic consequences. Prevention 
and recognition of the secondary causes of osteoporosis are first-line measures to lessen 
the impact of the disease. (Kosmin Dana Jacobs 2011) 
 
3.1 Types of osteoporosis 
3.1.1 Postmenopausal osteoporosis 
The process of bone loss proceeds much more rapidly after menopause. Postmenopausal 
bone loss is the results of increased bone desorption or in other term high turnover re-
lated to the reduction of estrogens production. Approximately 10 - 15 years after meno-
pause the initially accelerated bone metabolism normalizes and mainly age-associated 
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processes affect bone mass evolution. Postmenopausal osteoporosis and age-associated 
osteoporosis are referred to as primary osteoporosis type I and type II, respectively 
(Kosmin Dana Jacobs 2011) 
 
 
Table 1.Diagnostic categories for osteoporosis in postmenopausal women based on 
World Health Organization criteria 
 
Category 
 
Definition by bone density 
 
                             
Normal                                                                              
. 
Osteopenia                                                                       
 
 
Osteoporosis                        
. 
 
Severe osteoporosis                                                                   
 
A value for BMD that is not more than 1 SD below the young 
adult mean value 
A value for BMD that lies between 1 and 2.5 SD below the young 
adult mean value. 
 
A value for BMD that is more than 2.5 SD below the young adult 
mean value  
 
A value for BMD more than 2.5 SD or below the young adult 
mean in the presence of one or more fragility fractures 
 
 
 
 
. 
Abbreviations: BMD, bone mineral density; SD, standard deviation. (Srivastva.Manish 
MD, Chad Deal. MD Osteoporosis in elderly: prevention and treatment, Clin Geriatric 
Med 18 (2002) 529– 555) 
 
3.1.2 Primary osteoporosis 
Primary osteoporosis occurs in patients, in whom a secondary cause of osteoporosis 
cannot be identified, including juvenile and idiopathic osteoporosis. Idiopathic osteopo-
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rosis can be further subdivided into postmenopausal (type I) and age-associated or se-
nile (type II) osteoporosis. Juvenile osteoporosis usually occurs in children or young 
adults of both sexes. Type I osteoporosis (postmenopausal osteoporosis) occurs in 
women aged 50-65 years. This type of osteoporosis is characterized by a phase of acce-
lerated bone loss. This bone loss occurs primarily from trabecular bone. In this phase, 
fractures of the distal forearm and vertebral bodies are common. Type II osteoporosis 
(age-associated or senile) occurs in women and men older than 70 years. This form of 
osteoporosis represents bone loss associated with aging. Fractures occur in cortical and 
trabecular bone. In addition to wrist and vertebral fractures, hip fractures are often seen 
in patients with type II osteoporosis (Kosmin Dana Jacobs 2011) 
 
3.1.3 Secondary osteoporosis 
When osteoporosis occurs as a consequence of specific other diseases such as adrenal 
insufficiency, hyperthyroidism, hypogonadism, liver diseases or immobility, or if it re-
sults from corticosteroid treatment, it is also termed as secondary osteoporosis. (Roche 
Diagnostics 2009) 
 
As bones become more brittle with age due to bone mass loss, there is a greater risk of 
incurring a fracture. In the course of their lives, approximately 40 percent of women and 
about 10 - 15 percent of men suffer a fracture, especially of vertebral bodies, the femur 
and the forearm. The estimated incidence of femoral neck fractures is about 1.66 million 
per year worldwide. As life expectancy increases, the incidence of osteoporosis will in-
crease four fold. (Roche Diagnostics 2009) 
 
19 
 
3.2 Bone pathophysiology 
Osseous tissue, or bone tissue, is the major structural and supportive connective tis-
sue of the body. Osseous tissue forms the rigid part of the bone organs that make up 
the skeletal system. (Wikipedia) The bone tissue is composed of inorganic 70 percent, 
organic 22 percent and water 5 to 8 percent. Inorganic matter includes calcium hydrox-
yapatite 95 percent and impurities 5 percent. Organic matter is composed of type 1 col-
lagen 85 percent, other collagen and non colagenous proteins, which are( osteopontin, 
fibronectin, peptide growth factors and osteocalcin) and cells which are (osteoblasts, 
osteoclasts and osteocytes) (Rizzoli R 2005) 
Cortical bone accounts for 80 percent of bone skeleton and 20 percent of bone surface. 
It is found in shafts of long bones and outer surfaces of flat bones. Trabecular (spongy 
and cancellous) bone accounts for 20 percent of adult skeleton and 85 percent of bone 
surface. It is found at the end of long bones and inner parts of flat bones (Rizzoli R. 
second edition 2005; 1-4) 
Bone microstructure refers to trabecular thickness, spacing, connectivity and structural 
index. Early alteration in the micro architecture includes perforation and disappearance 
of trabeculae without major affects of body mass density. (Amman P. and Rizzoli R 
2003; 14 (suppl 3):513-518) 
Determination of bone strength includes bone geometry, cortical thickness, porosity, 
and trabecular bone morphology, intrinsic properties of bone tissue and rate of bone re-
modeling.  Body mass density which refers to density (mass per area rather than per vo-
lume), corresponds to the ratio between bone mineral content and bone scanned area. It 
is the major determinant of bone strength. Degree of mineralization also determines 
strength (Rizzoli R. 2005) 
Bone remodeling process is a surface based phenomenon that involves the removal of a 
quantum of bone by osteoclasts followed by the deposition of new bone by osteoblasts 
within the cavity formed. Knowledge of remodeling is essential to understand patholo-
physiology of osteoporosis. The primary function of bone remodeling is repair of micro 
damage and supply of calcium to maintain serum calcium levels. (Kasper D.L, Fauci A. 
S, Congo D. L, et al)  
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The remodeling cycle has four phases namely; resorption, reversal, formation and 
quiescence. Resorption phase takes 10 to 14 days while formation phase takes 150 days.  
During resorption phase 1 modeling, osteoclast recruitment, differentiation, activation 
and attraction to site of resorption occurs. During bone formation (phase 3 remodeling), 
osteoblasts undergo recruitment, differentiation and activation. They produce osteoid 
which later becomes calcified to mature bone. Some osteoblasts become trapped within 
the matrix and differentiate into osteocytes. Other differentiate into flattened lining cells 
that cover the bone surface while the rest undergo apoptosis (Kasper D.L, Fauci A. S, 
Congo D. L, et al) and (Ralston S.H 2001) 
Estrogen inhibits osteoclasts and stimulates osteoblasts. Osteblasts produce many 
growth factors and cytokines that mediate estrogen action. The result of estrogen defi-
ciency is increased osteoblast recruitment and perhaps activities (Compston J. E 2001; 
81:419-447) 
A fracture is considered to be osteoporotic (fragility fracture) if it is caused by relatively 
low trauma, such as a fall from standing height or less; a force which in a young healthy 
adult would not be expected to cause a fracture. 
 
 Overwhelming evidence has shown that the incidence of fracture in specific settings is 
closely linked to the prevalence of osteoporosis or low bone mass. In a prospective 
study of 8134 women older than 65 years in age, the study showed that the women with 
BMD of the femoral neck in the lowest quartile have 8.5-fold greater risk of sustaining a  
hip fracture than those in the highest quartile (Deplasl A et al 2004)  
 
 
 A fragility fracture (FF) is the clinically apparent and relevant (adverse) outcome in 
osteoporosis. Fragility fractures are fractures that result from low-level trauma, which 
means mechanical forces that would not ordinarily cause fracture. (Chrisopoulos Sad-
hana Bose Sergio 2010) 
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Hip fractures are already a major public health problem and this situation is expected to 
worsen in the future. They give rise both to suffering among patients and to a major 
economic burden on society in terms of cost of care. Hip fractures among the elderly are 
almost always caused by falling. As in other age groups, the reasons for falls among the 
elderly are multifactorial and relevant factors may depend on the individual, his or her 
environment, or his or her social circumstances. In contrast to other age groups, hip 
fractures are more common among elderly women than men, with women accounting 
for 75% of cases. (Furugren Lena and Laflamme Lucie 2007) 
 
A vertebral compression fracture occurs when the bones of the spine become bro-
ken due to trauma. Usually the trauma necessary to break the bones of the spine is quite 
large. The vertebrae most commonly broken are those in the lower back (emedicine-
health 2011). Most studies have shown that there is an exponential rise in the number of 
fractures with aging. In the European Vertebral Osteoporosis Study, the prevalence of 
vertebral deformity was 10 per cent in men age 50 to 54 years, rising to 18 per cent at 
age 75 to 79 years. In women age 50 to 54 years, the prevalence was only 5per cent; 
however, this rose to 24 per cent at age 74 to 79 years. Similar results were reported 
from other studies (Srivastava & Deal 2002) 
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3.3 Theories about Osteoporosis 
 
In the past, people thought a shortage of estrogen caused osteoporosis. People thought 
this because most patients were women who came down with osteoporosis after 
menopause, and because estrogen does influence the bone-forming activity of 
osteoblasts. However, close research has found that decline in estrogen levels is not a 
major cause of osteoporosis. Estrogen acts through two receptors called ERa and ERb.  
Osteoblasts express ERb, but it isn‟t clear that ERb agonists promote bone density. 
Estrogen supplements were given to post menopausal women to reduce risk of 
osteoporosis and for other reasons. This practice is employed much less now because 
the benefits of estrogen do not seem to outweigh the risks. 
There are conflicting theories about the cause of osteoporosis. Many researchers believe 
that it is brought on by faulty diet and lifestyle habits. Root causes, in addition to smok-
ing, are inactivity, poor diet, hormone deficiencies and imbalances, heredity and others. 
Uses of certain medications, such as antacids, thyroid, lithium, lasix, and chemotherapy 
are contributing causes. Certain drugs, such as steroids, like prednisone, may increase 
the risk of osteoporosis. This includes inhaled steroids for asthma or COPD. (Alice E. 
Marson2010) 
 
New research reveals why you should not clip your cell phone to your belt or pocket. 
The research warns that wearing a cell phone on your waist or hip may weaken an area 
of your pelvis.  Researchers found that bone density is lowered on the side where the 
mobile phone is carried. Bone density can be affected by electromagnetic fields emitted 
by a cell phone. (Marson Alice E. 2010) 
 
3.4 BMD assessment methods 
 
Osteoporosis is a disease in which screening of asymptomatic individuals may be bene-
ficial because it has a long preclinical course before the onset of fracture and because of 
the availability of both a reliable test to establish the diagnosis and treatments that have 
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been shown to reduce the risk of fractures. General consensus exists regarding recom-
mendation that osteoporosis screening with BMD measurements should be individua-
lized, but how this individualized approach to screening should be achieved remains 
controversial. There are several ways of assessing and screening.  
Bone densitometry is a medical term referring to the amount of matter per cubic centi-
meter of bones.  Bone density (or BMD) is used in clinical medicine as an indirect indi-
cator of osteoporosis and fracture risk (Wikipedia). Bone densitometry is an established 
method for assessing osteoporosis. A variety of different methods have been developed 
over the past 25 years. The two most commonly used methods are dual energy x-ray 
absorptiometry (DEXA) and quantitative ultrasound. DEXA is recommended and FDA 
approved for BMD measurement; it is precise, noninvasive, has low radiation exposure, 
and takes 10 minutes to administer. Because annual losses of bone mass normally seen 
with aging range from 1 per cent  per year, the precision error of current instruments 
(approximately 1 per cent  to 2 per cent with DEXA) cannot provide reliable informa-
tion at intervals shorter than 2 years. Therefore, if follow-up studies are desired, a min-
imum interval of 2 years is recommended. Exceptions to this include high dose steroid 
therapy that can result in rapid bone loss in a shorter interval (6 to 12 months) The Na-
tional Osteoporosis Foundation has published recommendations for BMD screening us-
ing DEXA (Srivastava, Deal 2002) 
A bone densitometry scan is a special type of X-ray test used to measure the calcium 
content of the bone, usually in the lumbar region (the lower back) and the hips. The ex-
amination is also called a DEXA-scan, QDR-scan or BMD (bone mineral density) mea-
surement. (Burnett & Pillinger 2005) 
Body Mass Density is one of the most important risk factor for fracture of substantial 
importance (Kanis J. A. & Gluer C.C 2001).  
Central hip and spine measurement by DEXA should be used for both risk assessment 
and follow up as they provide the most accurate and precise measurement of BMD. Hip 
is the preferred site in most individuals. Spine BMD may be the most sensitive indicator 
of bone loss in young individuals. The second way of measuring bone density is by 
quantitative computed tomography which is primarily used to the spine. Unlike DEXA, 
it can provide a true density (mass of bone per unit volume) since it is three dimensional 
24 
 
and it specifically analyses trabecular bone in vertebrae, eliminating posterior cortial 
elements of the spine.  (Johnnell & Brit. 1996) 
The use of biochemical bone turnover markers (BTMs) in clinical trials has been helpful 
in understanding the mechanism of action of therapeutic agents. However, their role in 
the care of individual patients is not well established. Biologic and laboratory variability 
in BTM values have confounded their widespread use in clinical practice. BTMs have 
little value for the diagnosis of osteoporosis, because dual-energy x-ray absorptiometry 
(DXA) is far superior for this purpose. However, markers of bone turnover give some 
indication about the future risk for bone loss and fractures. More importantly, they are 
useful in monitoring the efficacy of antiresorptive therapy in patients with osteoporosis. 
(Rosen, Clifford, Mulder 2011) 
Women who have borderline low BMD and elevated markers are at increased risk of 
losing bone health in the near future and may be candidates for pharmacologic interven-
tion. The resorption markers are also independent risk factors for fracture. (Srivastava, 
Deal, 2002) 
 
FRAX is a Web-based algorithm designed to calculate the 10-year probability of major 
osteoporosis-related fracture (clinical vertebral, hip, forearm, or humerus) and hip frac-
tures in men and women based on easily obtained clinical risk factors and bone mineral 
density (BMD) of the femoral neck. The NOF updated its U.S. guidelines in 2008 to 
incorporate FRAX and provide recommendations for its use in clinical practice. As rec-
ommended by the NOF, FRAX should be used when the decision to begin pharmaco-
logical treatment is uncertain. Patients meeting the following criteria are appropriate 
candidates for using FRAX to assist with a treatment decision: men aged 50 years and 
more and postmenopausal women, who are not on treatment and who have low bone 
mass (T-score between - 1.0 and - 2.5), no prior hip or vertebral fracture (clinical or 
morphometric), and an evaluable hip for dual x-ray absorptiometry (DXA) study. Al-
though BMD is not required for the FRAX algorithm, the NOF recommends using 
FRAX plus BMD for treatment considerations. If femoral neck BMD is not available, 
total hip BMD may be substituted, but use of BMD from sites other than the hip is not 
recommended (Nelson, Watts, 2010) 
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In the general population, previous fracture is an important risk factor for subsequent 
fracture. Using clinical and claims data from the USRDS, it has been reported that a his-
tory of any fracture resulted in a hazard ratio of 8.33 (5.04–13.74) for hip and 7.32 
(3.41– 15.71) for vertebral fracture and symptomatic vertebral fracture was associated 
with a more than sevenfold increased risk of subsequent fracture. Therefore a lateral X-
ray of the spine to evaluate for prevalent fracture may be a useful indicator of future 
fracture risk in CKD-5D (Toussaint, Elder, Kerr 2010) 
 
Quantitative computed tomography (QCT) has been used to determine BMD in CKD-
5D and can be used to distinguish BMD values in both cortical and trabecular bone 
compartments, while avoiding artifacts of vascular calcification and local degenerative 
changes that bedevil. 
DEXA evaluation sites (radius and tibia) as well as central sites (lumbar spine and prox-
imal femur) (Toussaint, Elder, Kerr, 2010). Although multiple technologies are availa-
ble for measurement of BMD, central dual-energy x-ray absorptiometry (DXA) of the 
hip (femoral neck or total hip) is the gold standard for diagnosing osteopenia or osteo-
porosis (Mauck, Clarke 2006; 81(5):662-672) 
4. ELDERLY AND OSTEOPOROSIS RISK FACTORS 
 
Risk factors are characteristics that increase the chances of developing a certain condi-
tion or disease. Risk factors for osteoporotic factors include age, gender, race, geograph-
ical region, diet, lifestyle, hormonal status, bone density, bone quality, body mass index 
and medical co morbidities (Table 2).  
 
Table 2.  Clinical Risk Factors Included 
  In the World Health Organization 
Fracture Risk Assessment Tool (FRAX) 
 Country of residence 
 Ethnicity (U.S. models only: Caucasian, black, Hispanic and Asian) 
 Age (allows ages between 40 and 90 years) 
 Sex 
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 Weight and height for calculating body mass index 
 Prior fragility fracture, including radiographic vertebral fracture 
 Family history of osteoporosis (parent with hip fracture) 
 Current smoking 
 Glucocorticoid use (prednisolone  5mg or more daily for 3 months and more, 
current or past) 
 Rheumatoid arthritis (physician-confirmed diagnosis) 
  Alcohol use ( 3 units daily or more) 
  Secondary osteoporosis 
 Bone mineral density, model also works without bone mineral density 
             (Nelson, Watts, 2010) 
 
4.1 Age 
‘ 
Fracture risk is much higher in the elderly than in the young. The frequency of hip frac-
tures in particular increases exponentially with age, especially after the age of 70, in 
both men and women, in most regions of the world. This increase in fracture risk is con-
sidered to be due to both the age-related decrease in bone mineral density of the prox-
imal femur and the age-related increase in falls, and is also related to the increased co 
morbidities of the elderly. (Dontas, Yiannakopoulos, 2007)  
 
BMD decreases and as a consequence the risk of osteoporosis increases with age. A 
significant increase in prevalence with each decade after age 60 has been demonstrated. 
The United States National Health and Nutrition Survey (NHANES) III survey of post-
menopausal women showed that the prevalence of osteoporosis in non-Hispanic white 
American women was 27 per cent  (50-59 years), 32 per cent(60-69 years) and 41 per 
cent for those70 years. A Previous estimate based on data from Rochester, Minnesota 
indicated a lower (though still high) prevalence – 14.8 per cent (age 50-59 years), 21.6 
per cent (aged 60-69 years), 38.5per cent (70-79 years) and 70per cent (80 years.)A 
Yorkshire based study showed a prevalence of 24 per cent in women aged 60-69 years 
(Scottish Intercollegiate Guidelines Network 2005) 
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4.2 Hormonal factors – gender differences 
Peak bone mass for women is lower than that one of men The increased bone loss in 
women after menopause and their increased propensity to falls compared to men, even-
tuates that the incidence of hip fractures in women of any age in the USA and Europe is 
about twice that of men at any age. In addition, because women live longer than men, 
more than 75 per cent of all hip Fractures are presented in women. Most researchers re-
port a 2:1 ratio of female: male hip fracture incidence over the age of 65. Other hormon-
al factors that increase fracture risks are premature menopause, primary or secondary 
amenorrhea, hyperthyroidism, hyperadrenocorticism and primary and secondary hypo-
gonadism in men (Dontas, Yiannakopoulos, 2007).  In females, the timing of the meno-
pause and subsequent oestrogen deficiency can also affect the rate of bone loss. Similar-
ly, men who are hypogonadal may have increased rates of bone loss and higher fracture 
rates in later life. (Anne Sutcliffe, 2005) 
Women are at greater risk of osteoporosis as they have smaller bones and hence lower 
total bone mass. Additionally, women lose bone more quickly following the meno-
pause, and typically live longer. Osteoporosis is less common in men but is still a signif-
icant problem. The rate of bone loss in men is less than that in women. In the Framing-
ham Osteoporosis Study annualized percent bone loss for women was 0.86 per cent to 
1.21 per cent at different sites and for men, 0.04 per cent   to 0.90 per cent. Secondary 
causes of osteoporosis are, however, more common in men, affecting approximately 40 
per cent of cases. Accepting reproductive factors and taking into account the increased 
influence of secondary factors in men, the risk factors in women also apply to men 
(Scottish Intercollegiate Guidelines Network, 2005) 
4.3 Demographic factors 
Northern countries appear to have an increased incidence compared to southern ones. 
Fracture incidence has been reported to be higher in white Scandinavian women than in 
North American women of comparable age. The lifetime risk of any osteoporotic frac-
ture at the age of 50 years has been estimated to be 46 per cent in women and 22 per 
cent in men in Sweden, with corresponding figures of 40 per cent and 13per cent in the 
USA. In addition, the lifetime risk and the age-specific risk of a hip fracture among 
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black men and women is approximately 50 per cent of that among white men and wom-
en. In India, osteoporotic fractures have a higher male to female ratio than among Wes-
terners (Dontas, Yiannakopoulos, 2007) 
Afro-Caribbean women have a higher BMD than white women at all ages due to a 
higher peak bone mass and slower rate of loss. White women have a 2.5-fold greater 
risk of getting osteoporosis (Scottish Intercollegiate Guidelines Network 2005) 
 
4.4. Medical and family history 
In families, bone mass is often lower in young women whose mothers have sustained 
osteoporotic fractures (Anne Sutcliffe, 2005) 
Fracture risk factors include a previous fragility fracture, family history of fracture or 
genetic factors, low bone mineral density, low body mass index, weight loss, resting 
pulse rate over 80 beats per minute, rheumatoid arthritis, use of corticosteroids, anticon-
vulsants, loop diuretics, and liability to falls (e.g., due to neuromuscular, cardiovascular 
and vestibular disorders, poor vision, dementia, use of certain drugs and polypharmacy) 
(Dontas, Yiannakopoulos, 2007) 
Lower BMD is found in women and men with a family history of osteoporosis, a family 
history being defined as a history of osteoporosis or brittle bones, kyphosis, or low 
trauma fracture after age 50 years. Individual BMD decreases as the number of family 
members with osteoporosis increases. Overall family history is a more sensitive predic-
tor of osteoporosis risk than maternal or paternal history alone Prevalence of a positive 
history in sisters is similar to prevalence reported for mothers. In one epidemiological 
study the greatest risk of categorical osteopaenia was in patients whose father had a his-
tory of osteoporosis (Scottish Intercollegiate Guidelines Network 2005) 
4. 5 Lifestyle risk factors 
All persons should be accustomed to a healthy balanced diet and a physically active 
lifestyle beginning from childhood and continuing throughout life, for normal skeletal 
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growth and aging. Adequate calcium intake has been demonstrated to be significant for 
increasing and maintaining bone mass. The importance of vitamin D for the intestinal 
absorption of calcium is also well documented. Hence, inactivity or immobilization, low 
dietary calcium intake, vitamin D deficiency, as well as cigarette smoking, caffeine in-
take, excessive alcohol consumption, and liability to falls, consist lifestyle risk factors 
for osteoporotic fractures (Dontas, Yiannakopoulos, 2007) 
4.6 Genetics 
Genetic factors account for as much as 80 per cent of the variance in peak hone mass 
and also influence the rate of bone loss. Studies demonstrate that genetic factors play an 
important role in regulating bone density, skeletal geometry and bone turnover as well 
as contributing to the pathogenesis of osteoporotic fracture itself (Anne Sutcliffe, 2005)   
The strong association between body mass and peak bone mass may partly result from 
shared genetic influences. (Chaudhri Tauseef, 2006)  
There is a genetic component to osteoporosis and having a parent with the condition or 
a history of hip fracture puts a person at greater risk of fracture. (Elliott Mary, 20111) 
4.7 Nutrition 
Like any organ in the body, the skeleton needs a balanced diet containing both macro-
nutrients (energy, proteins, fats and carbohydrates) and micronutrients (vitamin and 
minerals) for its normal development and maintenance. The two key nutrients for bone 
health are the mineral calcium and vitamin D. Calcium is a major structural component 
of the bone tissue and the skeleton also acts as a reservoir of calcium for maintaining 
calcium levels in the blood.  A large number of dietary components have been proposed 
as determinants of peak bone mass. The majority of work examining the effect of nutri-
tion on bone has focused on calcium and phosphorous due to them being major consti-
tuents of bone tissue. However the trace elements such as zinc, manganese and copper 
are necessary for growth development and maintenance of healthy bones (Chaudhn 
Tauseef, 2006)  
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Dietary components such as magnesium, fluoride, ascorbic acid and vitamin k work bio-
logically at the level of bone itself. Vitamin A, B6 and D are also necessary for healthy 
bone formation. (Singh, Willet, et al, 2002) 
There is clear evidence that adequate vitamin D and calcium intake also play significant 
roles in ameliorating the severity of osteoporosis and are necessary for optimal response 
to pharmacologic intervention (Chan, Scott, Sen, 2010). Most clinical guidelines rec-
ommend supplementation with calcium and vitamin D to optimize the efficacy of phar-
macologic therapies for osteoporosis (Chan, Scott, Sen, 2010) 
4.7.1 Calcium 
Calcium is essential for various body functions, such as nerve impulse transmission, 
muscle contraction, and blood clotting. About 99 per cent of calcium is found in the 
skeletal system but is leeched from the bones when the plasma calcium concentration is 
low. With low blood levels of calcium, parathyroid hormone is secreted, leading to the 
synthesis of calcitriol, which results in bone resorption and the release of calcium; if 
abundant calcium is present in the serum, this cycle will not occur and bone turnover 
will return to normal levels (Spangler, Phillips, Ross, Moores, 2011) 
Over the time even minor negative calcium balance leads to a reduced bone mass. Such 
negative calcium balance is not detectable by the commonly applied diagnostic test. It is 
therefore important when investigating patients with reduced bone mineral density that 
every mechanism possibly contributing to a negative calcium balance is carefully be 
considered (Deutschmann, Weger, Weger, kotanko, et al, 2002) 
A chronically low intake of calcium in the diet decreases bone mass and leads to an in-
creased risk of osteoporosis and bone fracture (Chan, Scott, Sen, 2010) 
4.7.2 Vitamin K 
Large amounts of vitamin K1 and K2, comparable to quantities contained in liver are 
found in cortical and trabecular bone compartments. Bone formation by osteoblasts in-
volves post-translational gammacarboxylation of glutamate residues on three bone pro-
teins: osteocalcin, matrix Gla protein, and protein S. Vitamin K is a necessary cofactor 
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for gammacarboxylation. When gammacarboxylation is lower than normal, the osteo-
calcin is undercarboxylated (also called “free” osteocalcin) and has a lower affinity for 
hydroxyapatite than the carboxylated protein. Serum concentrations of undercarbox-
ylated osteocalcin have an inverse correlation with concentrations of vitamin K1, and 
can be considered a marker of vitamin K status in bone. Vitamin K also decreases bone 
resorption, in part by inhibiting the activity of prostaglandin H synthase in osteoclasts, 
with a resulting decrease in the synthesis of prostaglandin E2. It has been found that el-
derly women with osteoporotic fractures have lower concentrations of serum vitamin K 
than controls. Serum concentrations of under carboxylated osteocalcin have an inverse 
correlation with BMD and a positive correlation with hip-fracture risk. Treatment with 
menatetrenone (menaquinone-4 belongs to the vitamin K2 group) decreased bone loss 
and increased concentrations of markers of bone formation in hemiplegic patients and in 
women treated with leuprorelin, and decreased the frequency of fractures in patients 
with osteoporosis. Some epidemiological data suggest that there is an inverse correla-
tion between the risk of an osteoporotic fracture and consumption of green vegetables 
containing high amounts of vitamin K1.Warfarin is a competitive inhibitor of vitamin K 
and decreases gammacarboxylation. Some, studies have shown that BMD is low and 
risk of osteoporotic fractures high in patients treated with warfarin. Warfarin does not 
affect the inhibition of bone resorption by vitamin K2, since this inhibition may be me-
diated by a side chain that warfarin does not compete with.( Veasy L George, 2001) 
 
Low dietary intake of vitamin K found in green leafy vegetables and cheese is asso-
ciated with low leafy vegetables and cheese is associated with low bone mineral density 
(BMD) and increased risk of fracture. (Sutcliffe Anne, 2005) 
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4.7.3 Vitamin D 
The role of vitamin D metabolites is primarily to maintain serum calcium and phosphate 
levels by directly promoting intestinal absorption of these ions as well as by activating 
bone resorption Failure of the vitamin D endocrine system during growth causes rickets, 
which is a prominent bone-deforming and sometimes life-threatening disorder. Vitamin 
D is also important in the maintenance of skeleton integrity in adults. Elderly people 
tend to have poor dairy calcium and vitamin D intakes, decreased sunlight exposure and 
dermal production of vitamin D, and diminished production of 1,25(OH)2 D3 with sec-
ondary hyperparathyroidism. In turn, vitamin D and calcium supplementation has been 
demonstrated to significantly increase BMD and decrease the incidence of osteoporotic 
fractures in the elderly (Rizzoli, Bonjour, Ferrari, 2001) 
4.8 Caffeine 
High caffeine intake has been associated with decreased BMD in post-menopausal 
women who have low calcium intakes (Sutcliffe Anne, 2005) 
Framingham study found that hip fracture risk was modestly increased with heavy 
caffeine use, but not for intake equivalent to one cup of coffee per day. „‟Since caffeine 
use may be associated with other behaviors that are, themselves, risk factors for frac-
ture, the association may be indirect‟‟ he says. „‟Further studies should be performed to 
confirm these findings.‟‟(Kiel, et al) 
 
Earlier research seemed to show that caffeine increases the loss of calcium, raising the 
risk of osteoporosis. Even in a fairly recent study, women aged 65–77 who drank more 
than 300 milligrams (mg) of caffeine daily and  about 18 ounces of regular coffee,  
showed greater bone loss over a three-year period than those who drank less. But the 
bone loss occurred only among a minority of women with an unusual variation in their 
cell vitamin D receptors. 
 
High caffeine consumption only seems to cause bone loss in elderly women who don‟t 
get enough calcium. As long as elderly women get the recommended 1,200 mg of cal-
cium a day, it should be safe for them to drink up to 300 mg caffeine or about 18 ounces 
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of coffee or its equivalent. Caffeine does not appear to adversely affect the bones of 
premenopausal women at all (Collins Karen, 2004) 
 
 
4.9 Smoking 
 
A history of smoking carries a modest but significant risk for future fractures. Current 
smoking is associated with a significantly increased risk of any kind of fracture in men 
and women with the effect waning slowly after a person stops smoking (Sutcliffe, 2005) 
 
4.10 Alcohol 
 
Although the influence of modest alcohol intake on the skeleton is uncertain it may af-
fect calcium metabolism and lead to reduced bone density. Heavy alcohol consumption 
is associated with a reduction in bone density and increased fracture risk. Ethanol may 
have a direct effect on osteoblasts (Sutcliffe, 2005) 
4. 11 Exercise 
Physical :activity is important to the skeleton since the associated weight bearing and 
muscular activity stimulate bone formation and increase bone mass, while immobiliza-
tion leads to rapid bone loss The positive responses of the skeleton are site specific to 
the loading pattern and the type of activity also influences the degree of response of the 
bone loading. The starting age of activity is important with the benefit to bone being 
doubled if the activity is commenced before or at puberty (Sutcliffe, 2005) 
 In adulthood, exercise appears to largely preserve bone rather than add new bone and in 
the immediate post-menopausal years it is unlikely that exercise will balance the effect 
of oestrogen deficiency. Individually targeted exercises focusing on muscle strength and 
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balance can improve gait, co-ordination, proprioception and reaction time in older 
people, decreasing the risk of falls (Sutcliffe, 2005) 
4.12 Secondary causes 
Among men, 30 per cent to 60 per cent of osteoporosis cases are associated with sec-
ondary causes (most commonly hypogo nadism, glucocorticoid use, and alcoholism); 
among perimenopausal women, more than 50 per cent of cases are associated with sec-
ondary causes (most commonly hypoestrogenemia, glucocorticoid use, thyroid hormone 
excess, and anticonvulsant therapy). The prevalence of secondary conditions is thought 
to be lower in postmenopausal women, but the actual proportion is unknown. (Mauck, 
Clarke, 2006; p.662-672) 
The cost-effectiveness of testing for secondary causes of osteoporosis is unknown be-
cause cost-effectiveness analyses have yet to be performed. In a chart review study, 
Tannenbaum et al examined this issue in perimenopausal and postmenopausal women  
found that a testing strategy consisting of 24-hour urinary calcium, serum calcium, and 
serum parathyroid hormone determinations in all women and serum thyrotropin mea-
surements in women receiving thyroid replacement therapy would be sufficient to diag-
nose secondary causes of osteoporosis in 86 percent of women adding 25-
hydroxyvitamin D would diagnose secondary causes in up to 98 per cent. However, this 
study was observational and small. (Mauck, Clarke, 2006; p.662-672) 
 
Jamal et al reported that the prevalence of abnormal test results in postmenopausal 
women with and without osteoporosis was similar, with the exception of low thyrotro-
pin. These authors concluded that routine laboratory testing (other than thyrotropin 
measurements) in otherwise healthy women with osteoporosis was not useful. Clearly, 
more research is needed in this area, especially in premenopausal and perimenopausal 
women and in men because the prevalence of secondary causes of osteoporosis in these 
groups is high (Mauck, Clarke, 2006; p.662-672) 
 
There are a number of clinical disorders that affect bone density and osteoporosis risk. 
This diverse group includes endocrine abnormalities, adverse effects of medications, 
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immobilization, and disorders of the gastrointestinal tract, renal disease and cancer. It is 
difficult to ascertain the true incidence of secondary osteoporosis but several studies 
have estimated that it may occur in 20 to 30 per cent of post-menopausal women and in 
more than 50 per cent of men with osteoporosis (Sutcliffe, 2005) 
EVALUATION 
Patients at risk for osteoporosis and related fractures should receive BMD testing by 
central DEXA. These patients include women age 65 years or older (regardless of risk 
factors), postmenopausal women under age 65 years with risk factors and postmeno-
pausal women with a history of nontraumatic fracture. In addition, testing should be 
considered for men age 70 years or older, for patients with diseases that may result in 
decreased bone strength, for patients taking long-term medications known to decrease 
BMD, and to assess response in patients receiving medications for the treatment of os-
teoporosis (Mac Laughlin, Raehl, 2008) 
 
 
5. PREVENTION AND TREATMENT 
 
In order to be able to identify patients at risk of fractures and optimize pharmacothera-
py, a thorough risk factor analysis is recommended. Two major areas of risk factor as-
sessment that should be considered, particularly for older individuals, include an as-
sessment of both “bone” and “non-bone” related risks. “Bone-related” risk factors are 
those factors associated with bone density. “Non-bone” risk factors are variables asso-
ciated with fracture risk unrelated to bone density, and may increase fracture risk irres-
pective of osteoporosis diagnosis. However they compound the risk of an osteoporosis 
end-point in a patient who has decreased bone density. (Mc Laughlin, et al 2006) 
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Age is not a drawback to start osteoporosis prevention strategies. Healthcare profession 
also have to educate themselves in order to assess and counsel their clients on the risk 
factors, nutrition recommendations, physical activities needs and pharmacological op-
tions as well as other life styles modifications required to obtaining and maintaining op-
timum bone density and health. The ones already diagnosed with osteoporosis can also 
benefit from employing the same assessment and educational principles to reduce or 
halt further bone loss  
There are now a number of treatments for osteoporosis that increase bone density and 
reduce the incidence of fractures. These drugs can be divided into anti-resorptive agents 
that inhibit osteoclast activity and anabolic agents that increase bone formation. Anti-
resorptive treatments include bisphosphonates, raloxifcne. Caicitonin, hormone re-
placement therapy (HRT) and vitamin D and calcium supplements. Teriparatide acts in 
an anabolic way and strontium ranelate is the first in a new class of drugs, dual acting 
bone agents (DABAs), that increase bone formation and reduces bone resorption (Sut-
cliffe, 2005) 
 
5.1 Non pharmacologic treatment 
Several non pharmacologic interventions for the prevention of osteoporotic fractures 
should be considered for all patients. The attainment of high peak bone mass early in 
life is one of the most important protective factors against reduced BMD later in life. In 
addition, strategies to maintain current bone mass for patients in later stages of life 
should be instituted.  Appropriate weight bearing exercise, minimization or elimination 
of various modifiable risk factors (example; smoking, excessive alcohol intake, main-
tenance of euthyroid status), and maintenance of adequate calcium and vitamin D intake 
should be recommended for all patients. (Mac Laughlin, Raehl, 2008) 
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5.2 Pharmacological treatment 
 
Pharmacological goals for osteoporosis include halting bone loss, improvement of 
BMD, and reduction in fragility fractures. However, drug therapies that have been 
shown to decrease fractures, particularly at the hip, should be used as hip fractures have 
the greatest impact from a patient and societal perspective. Pharmacological therapies 
for prevention of fractures in patients with osteoporosis include antiresorptive therapies 
such as the bisphosphonates (alendronate, ibandronate, risedronate) and selective oes-
trogen receptor modulator raloxifene and the anabolic agent teriparatide. 
 
Pharmacological treatments for osteoporosis can be broadly divided according to their 
mode of action. The majority of the agents act by slowing bone resorption, thereby pre-
venting the relentless bone loss underlying the disease 
 
Pharmacological treatment of osteoporosis is conducted in accordance with the prin-
ciples of evidence-based medicine, which incorporates information derived from the 
highest- quality investigations with clinical judgment and patient values to allow optim-
al clinical management. The important points in the choice of drugs are the preventive 
effects on vertebral, non-vertebral, and hip fractures, the consistency of the results of 
randomized, controlled trials, and long-term efficacy and safety. Meta analyses have 
demonstrated the reliable efficacy of several anti-resorptive agents for preventing verte-
bral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis alen-
dronate, risedronate, and raloxifene are efficacious agents for preventing vertebral frac-
tures in postmenopausal women with osteoporosis. Alendronate and risedronate have 
also been shown to be especially efficacious for the prevention of non-vertebral frac-
tures and hip fractures (Jun Iwamoto, 2008 et al) 
Antiresorptive therapies reduce osteoporotic fracture risk by increasing bone mass den-
sity and suppressing bone remodeling (Boonen, Vanderschueren, et al 2006) 
 
Treatments for osteoporosis are not the same as the way they are diagnosed, although 
some experts have recommended that they should be. In the United States, most experts 
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agree on the treatments outlined by the World Health Organization, which recommends 
that the given individuals be considered for pharmacological. 
The most commonly used osteoporosis treatments in Europe are currently the selective 
estrogen receptor modulator (SERM) raloxifene; the bisphosphonates alendronate, rise-
dronate, ibandronate and zoledronic acid; agents derived from parathyroid hormone 
(PTH); and strontium ranelate (Reginster, 2011) 
Bisphosphonates are compounds that bind avidly to hydroxyapatite crystals on bone 
surfaces and are potent inhibitors of bone resorption. Through inhibition of osteoclastic 
activity, they reduce bone remodelling, improve bone mineral density and are associated 
with reduced rates of fracture among women and men, although less well documented 
in the latter group. Alendronate (70 mg once weekly) and risedronate (typically 35 mg 
once weekly) are the most commonly used bisphosphonates worldwide. The most im-
portant benefit of bisphosphonates lies in the prevention of vertebral, nonvertebral and 
hip fractures in people who low bone mineral density (T score −2.5 or lower) or preva-
lent fractures, or both (Rahmani, Morin, 2009)  
 
According to results of large randomized, controlled trials, bisphosphates, raloxifene, 
calcitonin, parathyroid hormone and strontium ranelate effectively prevent fractures in 
postmenopausal women with osteoporosis. 
Low energy fragility fractures have been suggested as a result of complication of long-
term bisphosphonate therapy due to over suppression of bone turn over though bisphos-
phonates are widely used in practice, many questions still remain regarding the appro-
priate duration of use. Very few studies have evaluated the efficacy and safety of these 
medications beyond 5 years of therapy. (Shcmidt, Eltorner, et al 2010) 
 
 The primary goal of pharmacological therapy in patients with osteoporosis is to reduce 
the risk of future fracture, not just increase bone density. Currently, the pharmacological 
agents available for treatment of osteoporosis fall into 1 of 2 categories: antiresorptive 
agents or anabolic agents. All the currently available drugs except teriparatide are anti-
resorptive agents (figure 1).  These agents reduce bone resorption more than promote 
bone formation and thereby suppress bone turnover and loss, whereas anabolic agents 
stimulate bone formation more than reduce bone resorption (Mac Laughlin, Raehl, 
2008) 
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The figure below shows osteoporosis medications as they have been classified to their 
different classes of agents. 
 
Figure 1. Treatments of osteoporosis approved by Food and Drug Administration 
Subcategory                              Category                        Main category 
Alendronate 
Risendronate 
Ibandronate                                                                                                       
Zolendronate                                                                                                                                                                                           Osteoporosis prevention & treatment
Raloxifene                                                                                           
Nasal calcitonin 
Estrogen 
Anabolic agent 
Teriparatide 
 
 
                                     
Anabolic therapies stimulate bone formation, repairing defects at a micro architectural 
level leading to a substantial increase in BMD in the presence of adequate calcium and 
vitamin D status. A high proportion of patients with osteoporosis are at significant risk 
of calcium and vitamin D insufficiencies unless they receive supplementation. Anabolic 
agents may provide significant benefits to patients with severe osteoporosis (especially 
patients with previous osteoporosis-related fractures), as well as patients who have not 
tolerated or have had inadequate responses to antiresorptive therapy 
 Therapeutic decisions should be based on a balance between benefits and risks of 
treatment, which must be carefully considered in each particular case both by the physi-
cian and the patients, no single agent is appropriate for all patients and, therefore, treat-
ment decisions should be made on an individual basis, taking into account all measures 
of treatment effect and risk before making informed judgments about the best individual 
treatment option. (Reginster, 2011) 
All clinical trials of antiresorptive and anabolic therapies should be carried out in indi-
viduals who have good calcium and vitamin D status. Experts recommend that patients 
Antiresorptive 
Agents                                                                                                                     
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receiving antiresorptive and anabolic treatment for osteoporosis must have adequate 
calcium intake and optimal vitamin D to maximize benefits. 
 
5.2.1. Calcium 
Adequate calcium intake has been demonstrated to be significant for increasing and 
maintaining bone mass (Dontas, Yiannakopoulos, 2007)  
Evidence suggests that calcium intake is important during skeletal growth and peak 
bone mass development and there is a consensus that calcium supplementation may be 
effective in reducing bone loss in late post-menopausal women, particularly m those 
with low habitual dietary calcium intake (Sutcliffe, 2005) 
Calcium is the fifth most abundant mineral in the human body accounting for 1-2 per-
cent of adult body weight. Over 99 per cent of total body, calcium is found in the inor-
ganic phase of bones and teeth. It is absorbed depending on its interaction with other 
dietary constituents and physiological factors such as calcium regulating parathrormone 
requirements if optimal bone development is to be achieved. (Chaudhn, 2006)  
Due to a decrease in estrogen production after menopause, women‟s bodies are less able 
to retain calcium from dietary sources.  Calcium supplementation has been used for 
decades to prevent this calcium depletion, maintain bone mass, and prevent and treat 
osteoporosis (Spangler, Phillips, Ross, Moores, 2011) 
 
5.2.1.1 Calcium and bone health 
Healthy bones provide a strong foundation, allowing mobility and protection from in-
jury.  They also serve as a bank for important minerals, such as calcium, that help sup-
port numerous organs in our body.  Developing healthy bones begins at birth and 
proceeds throughout life.  The human body uses calcium to build healthy bones until 
about 30 years of age.  After the mid-30‟s, bone loss slowly begins to occur.  Women 
lose bone quickly after menopause.  Importantly, healthy habits can help to limit the 
bone loss that occurs. (Carmona, 2004) 
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5.2.1.2 Calcium absorption and excretion 
Dietary calcium absorption in adults with the usual intake is approximately 25 per cent 
to 35 per cent. Calcium absorption is dependent on several factors including age, vita-
min D and exposure of food to gastric acid.  (Chaudhn, 2006)  
Decreased calcium absorption occurs during menopause and maturity. When vitamin D 
is insufficient, calcium absorption is also decreased when the gastric acidity is low in 
the presence of liver, pancreatic, small bowel disease and mental and physical stress 
(Chaudhn, 2006)  
Elderly women have an impaired intestinal response to 1, 25 (OH). This defect may 
contribute to the negative calcium balance, secondary hyperparathyroidism and bone 
loss in aging women (Chaudhn, 2006)  
The bone calcium content is the result of whole body calcium balance which is deter-
mined by uptake in the gut and faecal and renal calcium excretion (Deutschmann, Weg-
er, kotanko, et al 2002) 
5.2.1.3. Calcium supplementation 
 
Calcium supplementation alone has been demonstrated to increase bone mineral density 
and to decrease the rate of fracture in post menopausal women (Chan, Scott, Sen, 2010) 
Calcium supplementation may prevent bone loss or even mildly increase BMD and 
some data suggest that it may minimally reduce fracture risk. 
 For patients with osteoporosis, calcium supplementation should be used as an adjunct 
to other pharmacological interventions rather than as monotherapy. The National Insti-
tutes of Health consensus conference guidelines suggest that women should optimize 
their elemental calcium intake to 1000 mg/d until menopause and increase it to 1500 
mg/d thereafter. Men should optimize their elemental calcium intake to 1000 mg/d until 
age 65, and then increase it to 1500 mg/d. (Mauck, Clarke 2006; p.662-672) 
Most experts recommend obtaining as much calcium as possible from foods because 
calcium in foods is accompanied by other nutrients that assist the body in utilizing cal-
cium (Chaudhn 2006)  
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The present recommended minimum daily calcium intake for adults ranges from 1000-
1300 mg. Even though calcium is relatively common in the diet, supplementation is fre-
quently necessary. Intake is often insufficient due to religious or dietary restrictions, lac-
tose intolerance. It is recommended that if dietary intake of calcium-rich foods is inade-
quate, supplements containing elemental calcium (calcium citrate and calcium carbo-
nate) should be taken. It should be noted that commonly used multivitamin supplements 
often do not contain sufficient calcium to make up for deficiency in the diet. Increasing 
calcium intake alone is insufficient for adequate maintenance of bone mass (Siew 
Pheng, et al 2010) 
5.2.2 Vitamin D 
Vitamin D is unique because it can be obtained both through skin exposure to sunlight 
and through food or supplements. Like all the other vitamins and minerals, calcium is 
available only through food or supplements although calcium and vitamin D foods are 
the preferred source of dietary. Several organizations suggest that older people may 
need supplements to meet their high needs for these nutrients. (Cheng, Johnson, Lewis, 
et al 2003) 
Vitamin D is necessary for optimal absorption of calcium and in housebound older 
people. Vitamin D deficiency contributes to osteoporosis and fractures through its ef-
fects on bone fragility and impaired muscle strength sunlight exposure, as a result of 
strict dress codes where most of the body is covered, may expose certain ethnic races to 
the risk of vitamin D deficiency. The benefit of a high consumption of fruit and vegeta-
bles and the resulting high intake of dietary alkali on skeletal integrity bas been empha-
sized (Sutcliffe, 2005) 
Addition of supplemental vitamin D to the diet has also been shown to reduce fracture 
rate in postmenopausal women (Chan, Scott, Sen, 2010) Vitamin D supplementation, 
particularly with the active form (calcitriol) may be theoretically important for frailer, 
institutionalized individuals or those with chronic health conditions (PTH disorders, 
chronic renal failure, and dialysis) due to the inability or reduced capacity to convert 
vitamin D to the active form. Vitamin D is an essential component that, along with para-
thyroid hormone (PTH), regulates serum calcium concentrations. Inadequate vitamin D 
intake may be a greater concern than poor calcium intake, as vitamin D may not be as 
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prevalent in the diet as calcium, and patients may be less aware of vitamin D require-
ments than calcium.  Low exposure to sunlight and poor renal function may also lead to 
decreased concentrations. Yet supplemental vitamin D, with or without calcium, has 
been shown to reduce fracture rates and may also have effects on muscle strength and 
risk of falling (Mac Laughlin, Raehl, 2008).  
 
Adequate intake of both calcium and vitamin D are an essential part of osteoporosis 
prevention, and no treatment regimen should be considered complete without these ad-
junctive therapies. There are numerous studies that have reported outcomes of supple-
mental calcium, vitamin D.  Adequate calcium and vitamin D intake is considered an 
essential component of osteoporosis prevention and treatment, yet many men and wom-
en over age 65 years consume only 600 mg of calcium daily. However, there is contro-
versy regarding calcium and vitamin D supplementation. There is no universal consen-
sus for the most appropriate daily dose though all groups recommend at least 1000 mg, 
and data are lacking regarding the most effective calcium salt. In addition, questions 
have been raised about the efficacy of calcium and vitamin D for prevention of frac-
tures. (Mac Laughlin, Raehl, 2008)   
 
In addition to its structural role, bone serves as the body‟s nutrient reserve of calcium. 
Ingested calcium is absorbed from the intestine in two ways: passively and by vitamin 
D-mediated active transport, both of which become less efficient with age. The efficien-
cy of calcium absorption decreases further in the presence of vitamin D insufficiency. 
Vitamin D status is generally determined by measuring the serum concentration of the 
major circulating form of vitamin D, hydroxyvitamin D [25(OH) D]. As people age, the 
skin‟s capability to synthesize vitamin D decline, intestinal vitamin D absorption also 
becomes less efficient. These changes may be compounded by lower exposure to the 
sun, as a result of diminished physical activity, and reduced dietary vitamin D intake; 
people who live at northern latitudes or who are housebound or living in an institution 
are at particular risk of vitamin D insufficiency . Adequate dietary calcium intake is crit-
ical in maintaining bone mass, whilst vitamin D plays a key role in modulating calcium 
homeostasis and maintaining muscular strength. There is therefore a strong rationale for 
giving both calcium and vitamin D supplements to prevent and treat osteoporosis (Boo-
nen, Vanderschueren, et al 2006)  
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After synthesis in the skin or ingestion through the diet, vitamin D3 is stored in the liv-
er, adipose tissue and muscle, where it has a half-life of about 60 days. It is converted 
into 25- hydroxyvitamin D3 in the hepatocytes. The serum concentration of 25-
hydroxyvitamin D3 is the best indicator of the nutritional and functional status of vita-
min D. Although circulating calcitriol (25-dihydroxyvitamin D3 or 1,25- dihydroxy 
cholecalciferol) is the vitamin D hormone regulating intestinal calcium and phosphate 
absorption, it is not an appropriate indicator of clinical vitamin D status in most cases 
(Hanley, Cranney, et al 2010). The few foods that naturally contain vitamin D for ex-
ample certain fish are not consumed regularly. Consequently, Canadians depend on for-
tified dietary sources or supplements to maintain adequate vitamin D status cases (Han-
ley, Cranney, et al 2010).  
The preferred source of calcium is foods such as dairy products. Some dietary sources 
of calcium include yogurt (400 mg per cup), milk (300 mg per cup), calcium-enriched 
orange juice (300 mg per cup), cheese (150-180 mg/oz), and canned salmon with bones 
(180 mg per 3 oz). Calcium supplements are an alternative means by which optimal cal-
cium intake can be reached in those who cannot meet this need by diet alone. Numerous 
calcium supplements are available in a variety of salts that can be used to supplement 
dietary calcium intake. The most commonly used calcium supplements are calcium car-
bonate or calcium citrate. Factors to consider in selecting an agent include absorption, 
convenience, and cost. Calcium absorption is generally maximal at individual doses of 
500 mg of elemental calcium. Calcium carbonate contains 40 per cent elemental cal-
cium, requires stomach acid for digestion and absorption, and is the least expensive op-
tion. It should be taken with meals in doses of no more than 500 mg of elemental cal-
cium at a time. Calcium citrate contains 21per cent elemental calcium, does not require 
stomach acid for digestion, and is more available but is more expensive than calcium 
carbonate. Calcium citrate can be taken with or without food in doses of no more than 
500 mg of elemental calcium at a time. Calcium citrate is the preferred calcium supple-
ment for patients who are hypochlorhydric or achlorhydric (including those taking gas-
tric acid–inhibiting drugs) and for patients with a history of kidney stones. The most 
common adverse effects of all calcium supplements are constipation, bloating, and gas; 
however, these adverse effects may be less frequent with calcium citrate. Patients taking 
medications whose absorption may be impaired by calcium (levothyroxine, fluoroquino-
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lones, and angiotensin-converting enzyme inhibitors) should also be advised to avoid 
taking calcium supplements within several hours of taking these medications. Vitamin 
D supplementation may prevent bone loss or mildly increase BMD and modestly reduc-
es vertebral and non vertebral fracture risk in vitamin D–deficient individuals. (Mac-
Laughlin, Raehl, 2008) 
5.2.3. Bisphosphonates (Alendronate, Risendronate, Ibandro-
nate, Zolendronate) 
Some treatments developed for post menopausal osteoporosis have also been registered 
for the prevention and treatment of corticosteroid-induced osteoporosis and presently 
bisphosphonates are the treatment of choice for this indication.(Cremers, Garnero, 
2006) 
 As far as medical treatment is concerned, the use of bisphosphonates constitutes a safe 
and effective therapeutic intervention for the treatment of osteoporosis.. (Brito, Battis-
tella, 2005) 
Bisphosphonates are powerful inhibitors of bone resorption.  These agents are increa-
singly used alongside anticancer treatments to prevent skeletal complications and re-
lieve bone pain they are also safe and effective treatment for induced bone loss.  
The bisphosphonates are stable analogues of pyrophosphate, but contain a carbon in the 
backbone of the molecule instead of oxygen. They have a strong affinity for bone hy-
droxyapatite. Oral bisphosphonates are poorly absorbed, hence the requirement for them 
to be taken on an empty stomach, with no food or drink for the next 30 minutes. Once 
absorbed, they rapidly localize to the skeleton, where they inhibit bone résorption by 
reducing recruitment and activity of osteoclasts and increasing osteoclast apoptosis.  
The bisphosphonates principally act by prevention of further bone loss and are asso-
ciated with moderate increases in BMD (Reginster, Akesson et al, 2011) 
In all published clinical trials, calcium and vitamin D supplements have also been used 
with the bisphosphonates as adjunctive therapy. In the RECORD study, concentrations 
of 25 (OH) , vitamin D were measured only in a very small subset of the patients. The 
vitamin D status of the majority of participants was unknown. Low serum concentra-
tions of vitamin D are widespread in the U.K and moderate vitamin deficiency in older 
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people results in poor bone and muscle strength. Serum 25 (OH) vitamin D concentra-
tions that correlate with clinically significant effects on muscle function and fracture 
prevention is at least  70 nmol/L  It is uncertain whether intake of Calcium/ vitamin D 
supplements has any increased benefits on the patients taking bisphosphonates.  
 
 
One recent meta-analysis evaluated the impact of vitamin D status on changes in bone 
mineral density in firstly patients with post menopausal osteoporosis bisphosphonates 
and secondly following discontinuation of bisphosphonates after a long term use, two 
patient groups were recruited. The first study population comprised of 112 women 
treated with a bisphosphonate. The second study population consisted of 35 women who 
had been on bisphosphonates for more than 5 years in whom the treatment agent was 
discontinued. Baseline BMD, changes in BMD following treatment, duration of treat-
ment, serum 25 (OH),  vitamin D, parathyroid hormone (PTH), urine C-terminal telo-
peptides of type 1 collagen (CTX) were obtained on the study participants. In the first 
study group, subjects with serum vitamin D concentrations (> 70 nmol/L) had a signifi-
cantly lower serum PTH level (mean [SEM] 41 ng/L). PTH concentrations of 41 ng/L 
or less was associated with a significantly higher increase in BMD at the hip following 
treatment with bisphosphonates compared to patients with PTH > 41 ng/L (2.5% [0.9] 
v/s -0.2% [0.9], P = 0.04). In the second study group discontinuation of bisphosphonate 
for 15 months after long-term treatment did not result in significant bone loss at the 
lumbar spine and total hip, although a trend towards gradual decline in BMD at the fe-
moral neck was observed. The data suggest that optimal serum 25 (OH) vitamin D con-
centrations may lead to further reduction in bone loss at the hip in patients on bisphos-
phonates.  
On the other hand, in order that patients with documented osteoporosis derive the ex-
pected clinical benefits from antiresorptive or anabolic therapy, calcium and vitamin D 
supplementation should be given throughout treatment with these therapies. (Boonen, et 
al 2006) 
The long-term bone safety of bisphosphonates has recently been questioned. Unusual 
fractures and delayed healing, possibly due to over suppression of bone turnover, have 
been reported In a  large longitudinal cohort study of women conducted to determine the 
effect of dosing frequency on bisphosphonate medication adherence, Of 211,319 study 
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patients, 177,552 (84 per cent) were taking weekly bisphosphonates vs. 33,767 (16 per 
cent) taking the daily prescription. Although significantly more patients taking the 
weekly compared with the daily bisphosphonates had adequate medication adherence, 
only about one third of patients in the daily dosing group and less than one half in the 
weekly dosing group achieved adequate adherence. Patients new to bisphosphonates 
had the worst medication adherence over the year (25.2 per cent for weekly vs 13.2 per 
cent for daily dosing; P<.001). The highest proportion of adequately adherent patients 
was among those continuing to take their existing weekly bisphosphonates; however, 
even in this group, only about 48% exhibited adequate medication adherence. (Recker, 
et al 2005) 
 
5.2.3.1 Alendronate 
 
Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to 
bone surfaces and inhibits bone resorption by osteoclasts. Oral alendronate 5 or 10 
mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal 
women with or without osteoporosis, in men with primary osteoporosis and in both men 
and women with or without osteoporosis receiving systemic corticosteroid therapy. His-
tomorphometric analyses have found that alendronate does not appear to impair bone 
quality. Alendronate reduced the risk of radiographic vertebral fracture, clinical verte-
bral fracture or hip fracture by 47 to 56 per cent in postmenopausal women who had ≥1 
existing vertebral fracture and in those with no existing vertebral fractures but who had 
osteoporosis. In a number of comparative trials in postmenopausal women with osteo-
porosis, alendronate 10 mg/day was found to be more effective at inducing sustained 
increases in BMD than intranasal calcitonin than and at least as effective as conjugated 
estrogens and raloxifene. Alendronate 70mg administered once weekly and 35mg twice 
weekly are as effective at increasing BMD as 10 mg/day in the patient group. Absorp-
tion and disposition of alendronate over the dosage range 5 to 80mg are linear. Beve-
rages (other than water), food and calcium supplements all reduce absorption of alen-
dronate. The drug is either excreted by the kidneys, the only route of elimination, or 
taken up and sequestered by bone, from where it is slowly released. The mean steady-
state volume of distribution of alendronate, excluding bone, is estimated to be at least 
28L. The renal clearance rate of the drug is 4.26 L/h and alendronate is not metabolized. 
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Excretion involves multiple phases that are initially rapid, then become very slow as 
alendronate is released from bone. The estimated mean terminal elimination half-life of 
alendronate is 10.5 years. (Sharpe, et al 2001) 
 
In clinical trials, alendronate was generally well tolerated when taken as recommended. 
The drug has been associated with upper GI tract adverse events, although the extent to 
which alendronate is responsible for these events has not been clearly established. 
Alendronate should be considered a treatment of choice in postmenopausal women with 
osteoporosis. Alendronate is also a suitable treatment option for primary osteoporosis in 
men and for corticosteroid-induced osteoporosis in both men and women. (Sharpe, et al 
2001)   
A prospective, randomized controlled trial, in a university based study of 6 months du-
ration. 1000 mg of calcium plus 10mg of alendronate daily significantly increased in 
nine densitometric parameters in the experimental group, although statistical signific-
ance was attained in only two of those parameters compared to the control group who 
received only 1000 mg of calcium that was observed with an increase of only one para-
meter whereas the remaining 11 presented either no alteration or a decrease Comparison 
of variations in mean UE BMD showed that there was a consistent increase in bone 
density in patients treated with alendronate plus calcium (0.03), whereas control group 
patients presented greater variability in UE BMD values, which were higher in some 
and lower in others (mean, _0.03). Mean increase in UE BMD in the experimental 
group was greater than in the control group in a marginally significant manner (P<0.14). 
No significant difference between the two groups was found in the BMD variation at the 
trunk (P<0.54). The author concluded that the use of alendronate had a positive effect 
on bone mineral density in SCI patients and therefore represents a potential tool for pre-
vention and treatment of osteoporosis in this population. (Brito, Battistella, 2005).  
 
The effects of alendronate on markers of bone turnover in postmenopausal women with 
osteoporosis have been compared with those of a number of other treatments alone and 
in combination with alendronate. In another clinical trial, continuous oral alendronate 
10 mg/day significantly reduced levels of serum markers of bone formation and urinary 
markers of bone resorption compared with placebo for at least 7 years in postmenopaus-
al women with osteoporosis. Alendronate had similar effects on bone turnover markers 
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in men with primary osteoporosis or osteoporosis associated with low serum testoste-
rone levels, both men and women with corticosteroid-induced osteoporosis and postme-
nopausal women without osteoporosis. (Sharpe, et al 2001). 
 Findings from randomized, controlled, head-to-head trials show that women who re-
ceived alendronate have greater gains in bone mineral density and greater reductions in 
bone turnover markers within 12 and 24 months of initiation than those who received 
risedronate or raloxifene. Although bone mineral density is a strong predictor of frac-
ture, differences in these surrogate markers may not translate into appreciable differenc-
es in fracture risk (Suzanne M. Cadarette et al 2008). Alendronate 5mg/day is effective 
in increasing vertebral BMD and stabilizing BMD at the femoral neck for at least 5 
years in postmenopausal women without osteoporosis, although it does not appear to be 
as effective in increasing BMD in this patient group as some HRT regimens.  The drug 
increases BMD in postmenopausal Asian women as effectively as in postmenopausal 
Caucasian women. There is evidence from FIT that alendronate 5 mg/day for 2 years 
followed by 10 mg/day for 1 to 2 years significantly lowers vertebral fracture incidence 
in postmenopausal women with low BMD but without osteoporosis. The recommended 
dosing instructions for alendronate 10 mg/day may be inconvenient for some patients on 
a daily basis. For these people, once weekly alendronate administration might be a more 
convenient option. Alternative dosing regimens of 70mg once weekly and 35mg twice 
weekly were as effective as 10 mg/day at increasing BMD and had no clear advantage 
or disadvantage in tolerability in a clinical trial (Sharpe, et al 2001) 
 
5.2.3.2 Risedronate 
 
Risedronate is a pyridinyl bisphosphonate that has been shown to be effective in the 
prevention and treatment of osteoporosis at a daily dose of 5 mg, a once-a-week dose of 
35 mg, a dose of 75 mg on 2 consecutive days a month, or a once-a-month dose of 150 
mg. Treatment with risedronate for 36 months reduced the risk of vertebral fractures by 
41 per cent and non vertebral fractures by 39 per cent  relative to placebo in women 
with at least one existing vertebral fracture17 and the risk of hip fractures by 40 per cent 
relative to placebo in women aged 70 to 79 with osteoporosis.  Retrospective analyses 
showed that risedronate significantly reduced the incidence of nonvertebral and clinical 
vertebral fractures within 6 months. (Boonen, et al 2010). 
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  Given the aging population and the predicted increases in the incidence of osteoporosis 
and related fractures, information on the relationships between aging and fracture inci-
dence and the effect of treatment on fracture risk as the population ages would be of in-
terest.  The large database developed during the risedronate clinical trial program pro-
vides the opportunity to explore these relationships further in a large population of 
postmenopausal women with osteoporosis. The effect of age on fracture risk is frequent-
ly examined by holding other risk factors, such as bone mineral density (BMD), con-
stant, although because other risk factors change as patients‟ age, this approach may not 
be optimal. Using pooled information from several risedronate, analyses were con-
ducted to quantify the effect of age on fracture risk and the benefit of risedronate treat-
ment for different age groups without adjusting for BMD. Prediction of fracture risk in 
different age groups provides information that clinicians and patients need as they 
weigh treatment and lifestyle options. Results from observational studies suggest that 
risedronate may reduce the risk for nonvertebral fracture (clavicle, hip, humerus, leg, 
pelvis, and wrist) within 12 months more effectively than alendronate or nasal calcito-
nin (Cadarette, et al, 2008) 
 
5.2.3.3 Zoledronic acid 
 
This is the most potent bisphosphonate, zoledronic acid, which is administered once 
yearly as an intravenous infusion, has been developed to overcome the limited gastroin-
testinal absorption and poor patient adherence associated with oral bisphosphonates. 
Zoledronic acid has also been found to increase BMD in a similar manner when given 
as an intermittent i.v. infusion. In August 2007, zoledronic acid became the first bis-
phosphonate to receive FDA approved labeling for once-yearly administration in the 
treatment of osteoporosis in postmenopausal women (Reginster, 2011) .  
 
2 large clinical trials that compared yearly infusion of 5 mg of zoledronic acid with pla-
cebo: one involved postmenopausal women at high risk of fractures have been identi-
fied. The HORIZON trial included 7765 postmenopausal women aged 65-89 years with 
BMD T-scores of -2.5 SD or lower at the femoral neck, with or without evidence of ex-
isting vertebral fracture, or a T-score of-1.5 SD or lower with evidence of >2 mild or >1 
moderate vertebral fractures, just under two-thirds of women had baseline fractures. Pa-
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tients were randomized to receive a 15-minute, 5 mg infusion of zoledronic acid (n = 
3889) or placebo (n = 3876) at baseline, 12 months and 24 months; follow-up continued 
to 3 years. The primary endpoints were new vertebral fracture in patients not taking 
concomitant osteoporosis medications and hip fracture in all patients. The relative risk 
of vertebral fracture with zoledronic acid was 0.30 (95% CI 0.24, 0.38). New vertebral 
fractures occurred in 3 percent of women in the zoledronic acid group and in 11% of 
women in the placebo group. In the HORIZON trial, the hazard ratio for hip fracture 
with zoledronic acid was 0.59 (95% CI 0.42, 0.83). At 3 years, the incidence of hip frac-
ture was 1 percent (52 women) in the zoledronic acid group and 3 per cent (88 women) 
in the placebo group. The incidence of any clinical fracture, clinical vertebral, or non-
vertebral fracture in postmenopausal women aged 75 and older was significantly lower 
in the ZOL group than in the placebo group over 3 years (P<.001, P<.001, and P=.002, 
respectively). A similar finding has been shown for any clinical fracture and clinical 
vertebral fractures at 1 year (P=.03 and P=.009, respectively), but the incidence of non-
vertebral fracture at 1 year and hip fracture at 1 and 3 years was lower for the ZOL 
group although not significantly (Black, et al,2007) 
 
In another trial that involved men and women with a recent hip fracture.  Zoledronic 
acid was also found to decrease mortality by 28 percent compared with placebo in the 
study involving patients with a recent hip fracture (number needed to treat = 29). The 
use of zoledronic acid was associated with a risk reduction in vertebral fractures (RR 
0.30, 95% CI 0.24–0.38; number needed to treat = 14) and nonvertebral fractures (RR 
0.75, 95% CI 0.64– 0.87; number needed to treat = 38). (Lyles, et al. 2007) 
 
 5.2.3.4 Ibandronate 
 
It is a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly 
intravenous formulations for intermittent administration, has been approved for the 
treatment of osteoporosis in postmenopausal women in the EU, the US and many other 
countries worldwide. The once-monthly oral formulation has also been approved for the 
prevention of postmenopausal osteoporosis in the US. Ibandronate is an effective and 
generally well tolerated bisphosphonate that offers an alternative to other bisphospho-
nates as a first-line treatment for postmenopausal osteoporosis. It occupies a similar po-
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sition with respect to the prevention of osteoporosis in postmenopausal women at risk 
for the disease. The once-monthly oral and quarterly intravenous dosage regimens have 
the potential to improve treatment adherence and persistence, and hence clinical out-
comes, compared with more frequently administered oral bisphosphonates. Intravenous 
ibandronate may be particularly useful for postmenopausal osteoporotic women who are 
noncompliant with, or are unable to tolerate or receive, oral bisphosphonates. Intermit-
tent ibandronate extends the range of pharmacological therapies for the treatment and 
prevention of postmenopausal osteoporosis it inhibits osteoclast-mediated bone resorp-
tion. In clinical trials in postmenopausal women with osteoporosis, approved oral and 
intravenous ibandronate dosage regimens reduced bone turnover, and increased lumbar 
spine and proximal femur bone mineral density (BMD) and mechanical strength. Bone 
newly formed in the presence of ibandronate is normal in terms of quality and minerali-
zation. Absorption of oral ibandronate, although rapid, is low (bioavailability 0.63%) 
and markedly impaired by food and beverages (other than plain water). After initial sys-
temic exposure, ibandronate is either sequestered in bone (≈40–50% of the circulating 
dose in postmenopausal women) or excreted in the urine (renal clearance of the drug is 
linearly related to creatinine clearance). Ibandronate only moderately bound to plasma 
proteins and does not undergo hepatic metabolism; hence, it has a low potential for dis-
placement from plasma proteins and metabolic drug-drug interactions with other medi-
cations. (Frampton, Perry, 2008).  
 
Subsequent clinical studies have provided further evidence of the positive effects of ex-
tended-interval ibandronate administration in reducing the risk of vertebral fractures 
through increasing bone mineral density and reducing bone turnover without compro-
mising bone quality. (Chesnut, 2006).   
 
Ibadronate is approved for the treatment of osteoporosis in postmenopausal women in 
the EU and the US. Currently, it is the only bisphosphonate available in both oral and 
injectable forms. The recommended available dosage regimens are 150 mg orally once 
monthly and 3 mg intravenously ( injected over a period of 15-30 seconds) every 3 
months. The once monthly oral formulation of ibandronate is approved for the preven-
tion of osteoporosis in the postmenopausal women in the US. The once daily oral for-
mulation of ibandronate is not commercially available. Patients prescribed once 
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monthly oral ibandronate should take their tablet preferably on the same date each 
month and after an overnight fast (6 hours or more) and /or 1 hour or more before the 
first food and drink of the day or any other oral medication or supplement. The tablet 
should be taken with plain water while sitting or standing in an upright position and pa-
tients should not lie down for 1 hour afterwards. (Frampton, Perry, 2008).  
 
5.2.4 Other treatments 
 
5.2.4.1 Raloxifene 
 
Is a selective estrogen-receptor modulator, has estrogenic activity in some tissues for 
example bone and antagonist for effects in others example breast. Daily use of ralox-
ifene (60 mg/d) increases bone mineral density and has been shown to diminish the risk 
of estrogen-receptor–positive invasive breast cancer by 55% to 90%.  (Rahmani, Morin, 
2009). Raloxifene selectively interacts with estrogen receptors, exerting an estrogen 
agonist effect in some areas (bone and lipid metabolism) while acting as an estrogen 
antagonist in others (breast and uterus). Raloxifene is contraindicated in patients with a 
history of venous thromboembolic events and should not be recommended for preme-
nopausal women or women concurrently using estrogen replacement therapy. (Karen F. 
Mauck and Bartl Clarke 2006). Raloxifene was the first SERM approved for the preven-
tion and treatment of osteoporosis in postmenopausal women The MORE study re-
cruited 7705 women aged 31-80 years, at least 2 years postmenopausal with osteoporo-
sis defined as low BMD or radio graphically apparent vertebral fractures. Prior to ran-
domization, patients were stratified to one of two study groups at the time of radiogra-
phy screening: 5064 were assigned to study group 1 if they had no vertebral fractures 
but a femoral neck or lumbar spine BMD T-score of >2.5 SD; and 2641 were assigned 
to study group 2 if they had vertebral fractures. Within each sub study, women were 
randomly assigned to treatment with raloxifene 60 or 120 mg/day or placebo for 3 
years. Only the results for the 60 mg/day dose were presented, because this is the cur-
rently marketed dose in Europe. The relative risk of vertebral fracture with raloxifene 
was 0.70 (95% CI 0.6, 0.9). New vertebral fractures occurred in 113 (15%) women in 
the raloxifene group and in 163 (21%) women in the placebo group. These results gave 
RRR of 30%, an ARR of 7 per cent and an NNT of 16 for vertebral fracture over 3 
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years. The clinical efficacy of raloxifene against hip fractures over 3 years has not been 
investigated in a pivotal phase iii study (Reginster, 2011) In a meta-analysis of 7 trials 
in which postmenopausal women were given raloxifene or placebo, raloxifene was as-
sociated with a risk reduction in vertebral fractures (RR 0.60, 95% CI 0.50–0.70; num-
ber needed to treat = 2381 to 99 across the range of fracture risk for 2 years of treat-
ment).There was little effect of raloxifene on the risk of other fractures. The RUTH (Ra-
loxifene Use for The Heart) study, involving postmenopausal women at high risk of 
cardiovascular disease, showed that raloxifene had no effect on the risk of cardiovascu-
lar death, coronary artery disease or stroke. Raloxifene, like estrogen, is associated with 
an increased risk of venous thromboembolism (OR 2.08, 95% CI 1.47–3.02).In practice, 
raloxifene is generally well tolerated, with transient occurrence of hot flashes and leg 
cramps in less than 10% of patients. (Cranney, et al.2002, Collins , et al. 2006).  To the 
author‟s knowledge, no studies have compared the relative effectiveness of raloxifene 
versus bisphosphonates or calcitonin in reducing fracture risk. Further comparative ef-
fectiveness studies may help to clarify the relative effectiveness of osteoporosis treat-
ments 
 
5.2.4.2 Calcitonin 
 
It has a rapid but short-lived effect on osteoclast function, decreasing the rate of bone 
resorption. It is given either subcutaneously or intranasally with variations in dose and 
frequency of administration. Although it reduces the risk of vertebral fractures, this evi-
dence is inconsistent and it is best recommended in those who are unable to tolerate 
other treatments. Side effects include flushing, vomiting, diarrhea and local irritation, 
when it is  
Injected, administered through nasal crusting or secretion when taken intranasally. Cal-
citonin is very useful in the acute management of vertebral fractures where it appears to 
confer analgesic properties, leading to a reduction in pain within two weeks with subse-
quent improvement in mobility (Sutcliffe, 2005). Calcitonin and parathyroid hormone 
are involved in the regulation of bone turnover, and hence in the maintenance of cal-
cium balance and homeostasis. By evaluating the efficacy of calcitonin for the treatment 
and prevention of GIO in a meta-analysis, the results showed that calcitonin prevented 
bone loss at the spine and forearm by about 3 percent after the first year of therapy. 
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There was no effect on bone loss at the hip. Calcitonin was not statistically different 
from placebo at preventing fractures of the spine and long bones, such as hip fractures. 
Calcitonin was associated with a fourfold greater incidence of side-effects than placebo, 
mostly nausea and facial flushing. The clinical usefulness of calcitonin for the treatment 
or prevention of GIO is still unclear. The American Committee of Rheumatology, for 
example, considers calcitonin as a second-line agent in patients with a low BMD who 
cannot tolerate bisphosphonates (Vermaat, Kirtschig, 2008) 
Calcitonin is a 2-amino-acid peptide that inhibits osteoclast-mediated bone resorption. 
The salmon form is approximately 40-fold more potent than the human form, due to 
conformational flexibility Data are available that support the use of salmon calcitonin 
for treatment of vertebral fractures in women with osteoporosis, though nonvertebral 
fracture data are generally lacking (Reginster, 2011). Salmon calcitonin nasal spray is 
FDA-approved for the treatment of osteoporosis at a dose of 200 IU in alternating no-
strils each day. It inhibits bone resorption by osteoclasts, thereby preventing bone loss 
and vertebral fractures, but it has not been shown to reduce nonvertebral or hip frac-
tures. This drug may also decrease the pain associated with acute or sub acute vertebral 
fractures. There are no contraindications to calcitonin use other than hypersensitivity to 
the drug; common adverse effects include nasal symptoms and rhinitis in about 12% of 
patients. Because of the availability of other medications that have better efficacy in 
fracture reduction, calcitonin is not considered first-line treatment for osteoporosis 
(Mauck, Clarke, 2006) „ 
 
In the Prevent Recurrence of Osteoporotic Fractures (PROOF) study, intranasal salmon   
(100, 200, or 400 IU daily) was compared with placebo in 1255 postmenopausal women 
with preexisting vertebral compression fractures.  After five years of follow-up, 200 IU 
of salmon calcitonin daily was associated with a 33% decrease in the rate of new verte-
bral fractures (NNT = 13; RR = 0.67; 95% CI, 0.47–0.97; p = 0.03). No significant dif-
ferences in the rate of new vertebral fractures were demonstrated in patients taking 100 
or 400 IU of salmon calcitonin. One factor that may have limited the findings of this 
study was the high dropout rate. Fifty-nine percent of patients withdrew from the study 
early, though rates of discontinuation were similar in all treatment groups. In addition to 
the ability to prevent future vertebral fractures, salmon calcitonin also appears to pos-
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sess analgesic activity. Thus, this agent may be useful in the treatment of acute vertebral 
fractures, in which back pain can be significant (Mac Laughlin, Raehl, 2008) 
 
5.2.2.3 Estrogen / Hormone therapy 
Although estrogen replacement therapy (ERT) was used as an antiresorptive therapy for 
many years for the prevention or treatment of osteoporosis, there was a paucity of data 
from clinical trials demonstrating a reduction in the risk of fractures, particularly at the 
hip. Previous recommendations for routine use of estrogen were based on observational 
studies and Meta analyses that indicated an approximate 30–60% reduction in vertebral 
and non vertebral fractures with five or more years of ERT use (Mac Laughlin, Raehl 
2008).  
 
This therapy comprises Treatment with oestrogen with the addition of cyclical or conti-
nuously administered progestogen in women with a uterus. Prospective cohort studies 
and large randomized clinical trials have demonstrated its efficacy in terms of preven-
tion of post-menopausal bone loss. Findings from the Women's trials performed in the 
United States (US), have shown beneficial effects of continuous combined oestrogen 
and progestogen on fracture outcomes This WHI study was curtailed after five years 
due to the excess number of breast cancer cases; in addition those using HRT were 
shown to have a higher incidence of coronary events, strokes and pulmonary emboli. On 
the basis of these findings HRT is no longer recommended as a long-term therapy for 
the prevention of bone loss or treatment of established disease in the older woman (Sut-
cliffe, 2005).  
 
The WHI study was the largest randomized, prospective trial to evaluate the risks and 
benefits of estrogen with and without a progestin in healthy postmenopausal women. 
The festrogen plus progestin group included 16,608 women with an intact uterus who 
received either 0.625 mg of conjugated equine estrogen (CEE) plus 2.5 mg of medroxy 
progesterone acetate or placebo. The estrogen-only group included 10,739 women with 
a prior hysterectomy, who received 0.625 mg of CEE daily or placebo. After an average 
follow-up of 5.2 years, estrogen plus progestin was discontinued due to a slightly in-
creased risk of breast cancer (NNH = 237). Based on the results of the WHI study, es-
trogen should not be used to prevent CHD or as first-line therapy for postmenopausal 
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osteoporosis and should generally be used at the lowest therapeutic dosage for the 
shortest time possible to control significant menopausal symptoms (Example  hot flash-
es) Strong consideration of other medications that have been shown to decrease the risk 
fractures and weighing of the risks and benefits are recommended before using estrogen 
solely to prevent osteoporosis. (Mac Laughlin, Raehl, 2008).  
 
5.2.2.5 Teriparatide.  
Teriparatide is a recombinant form of parathyroid hormone (PTH).It may increase or 
decrease BMD, depending on the route of administration. Given as an exogenous, in-
termittent injection, teriparatide increases BMD by stimulating bone formation. The ef-
ficacy of teriparatide for reducing the incidence of new vertebral fracture was examined 
in the FPT Women were eligible for inclusion if they were at least 5 years postmeno-
pausal with at least one moderate or two mild vertebral fractures on radiographs of the 
thoracic and lumbar spine. For women who had fewer than two moderate vertebral frac-
tures, an additional inclusion criterion was a BMD T-score of the lumbar spine or prox-
imal femur at least -1 SD. Women were randomized to daily injections of teriparatide 
20 \ig (n = 541), teriparatide 40 ng (n = 552) or placebo (n = 544). In the FPT the rela-
tive risk of vertebral fracture with teriparatide 20 ng was 0.35 (95% CI 0.22, 0.55). New 
vertebral fractures occurred in 5% of women in the teriparatide 20 ng group and 14% of 
women in the placebo group. These results give an RRR of 65 per cent , an ARR of 9 
per cent and an NNT of 12, which means that 12 patients would need to be treated for 
21 months (the median treatment duration) to prevent one vertebral fracture of any se-
verity. Efficacy against hip fractures has not been demonstrated in a pivotal phase III 
study with teriparatide, (Neer,  et al 2001) The most common adverse effects associated 
with teriparatide include injection-site pain and swelling (<3.3% of patients), nausea 
(8.5%), headaches (7.5%), leg cramps (2.6%), and dizziness (8%). These effects re-
sulted in discontinuation rates of 6–19% in clinical trials. Clinical trial data have sug-
gested that the frequency of transient hypercalcemia was 1.5per cent in women and 0 
per cent in men given placebo, versus 1 per cent in women and 6 per cent in men treated 
with teriparatide. Clinical trials of teriparatide have included treatment algorithms to 
address hypercalcemia that occurs throughout the treatment course, including recom-
mendations for reducing calcium intake to no more than 1000 mg/day or reducing teri-
paratide injection frequency to once every other day. Clinical manifestations of hyper-
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calcemia were not reported among these cases in clinical trials. Allergic reactions, in-
cluding dyspnea, urticaria, and chest pain, have occurred in less than 1 in 1000 teripara-
tide recipients. Teriparatide use should be avoided in patients at increased baseline risk 
for osteosarcoma, such as patients with Paget‟s disease, unexplained elevations in alka-
line phosphatase, , or prior radiation therapy involving the skeleton. Teriparatide should 
not be used for more than two years because safety and efficacy for longer periods have 
not been evaluated. Since the commercial launch of teriparatide in December 2002, a 
worldwide safety monitoring program has identified one confirmed case of osteosarco-
ma in a patient treated with teriparatide.  Causality was not established. This one osteo-
sarcoma case among more than 300,000 patients treated with teriparatide equates to a 
background annual incidence of 1 in 250,000.40The role of the pharmacist in the man-
agement of osteoporosis has been documented primarily in the setting of osteoporosis 
screening. More recent evidence demonstrates pharmacists taking expanded roles in 
disease management, such as the development of pharmacist-run clinics. A pharmacist-
operated teriparatide clinic has been developed to address the black-box warning, the 
subcutaneous route, monitoring for potential adverse effects, patient education, and the 
high cost (example to provide assistance with insurance coverage) The average whole-
sale price of a month‟s supply of teriparatide is $629.17, compared with a range of 
$73.82–$86.81 for antiresorptive agents. Many insurance plans require documentation 
of failure of or intolerance to previous antiresorptive therapy before they will agree to 
pay for teriparatide., Lundkvist et al reported that teriparatide monotherapy is cost-
effective if used in women who are 69 years or older, have femoral neck T-scores of –
3.0 or worse, and have a history of a vertebral fracture. Because of its black-box warn-
ing, route of administration, and cost, teriparatide is not considered the drug of choice 
for typical management of osteoporosis. Appropriate candidates for teriparatide therapy 
include men and women at high risk of an osteoporotic fracture, patients unable to tole-
rate antiresorptive therapy, and patients who have worsening BMD or who suffer a frac-
ture while receiving antiresorptive therapy. Consideration may also be given to patients 
with glucocorticoid- induced osteoporosis, although teriparatide is not labeled for this 
condition. Teriparatide should be initiated as monotherapy, as most antiresorptive 
agents given in combination with it have been shown to attenuate its effect. Patient 
monitoring should include a one-time nadir serum calcium level and annual DXA scans. 
After two years of teriparatide therapy, bisphosphonate therapy is recommended to 
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maintain BMD improvements. Prospective studies are needed to assess teriparatide‟s 
ability to reduce rates of hip and wrist fractures. Data are also needed to verify teripara-
tide‟s long-term safety (Michael, Abu-Baker, 2008) 
 
5.2.2.6 Strontium Ranelate 
Strontium ranelate is a divalent strontium salt comprised of two molecules of stable 
strontium and one molecule of ranelic acid. It is a bone seeking agent capable of in-
creasing bone formation and reducing bone resorption, thereby uncoupling and reba-
lancing bone turnover in favour of bone formation. In vitro, low-dose (1mmol/L) stron-
tium ranelate for 24 hours stimulated replication of osteoprogenitor cells (by 30–50%) 
and increased collagen and noncollagen protein synthesis (by 35%) in osteoblasts in cul-
tures from rat calvariae (all p < 0.05 vs control).  Strontium ranelate also increased (p < 
0.05 vs control) the differentiation and function of primary murine osteoblasts and pro-
moted (p < 0.05 vs control) the differentiation and mineralization of primary human os-
teoblasts with enhanced osteocyte-like cell formation at some concentrations.  The drug 
triggers mitogenic signals, such as the activation of protein kinase C and p38 mitoge-
nactivated protein kinase and increases the expression of the immediate early genes, c-
fos and egr-1, which are involved in osteoblast replication.  An in vitro study also sug-
gested that strontium ranelate induced osteoclast apoptosis via the CaSR through a sig-
nalling pathway similar to, but also different in certain respects from, that of calcium. 
This enables strontium ranelate to potentiate calcium-induced apoptosis, and vice versa, 
acting together with calcium to inhibit bone resorption. In women with osteoporosis in 
whom long-term treatment with strontium ranelate was shown to improve bone micro-
architecture, which may, in turn, improve bone biomechanical competence and explain 
the antifracture efficacy of strontium ranelate. Significant improvements (all p £ 0.05 vs 
placebo) in cortical thickness (+18%), trabecular number (+14%), structure model index 
(-22%) and trabecular separation (-16%), as assessed by microcomputer tomography, 
were observed in 3-year biopsies from 41 women who received strontium ranelate 2 
g/day or placebo in clinical trials. Treatment with strontium ranelate 2g/day for 2 
months had no significant effect on in vitro bleeding time or most other haemostatic pa-
rameters or anticoagulant proteins in 35 elderly women (aged ‡65 years) with osteopo-
rosis. In a small prospective cohort study, strontium ranelate 2 g/day for 12 months was 
shown to increase (p = 0.033) lumbar spine BMD (and reduce bone markers to baseline 
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levels.  In 19 (evaluable) women with postmenopausal osteoporosis who had previously 
been treated with teriparatide 20 mg/day for 18 months and had experienced a signifi-
cant (p < 0.001) increase in BMD during this period, suggesting that strontium ranelate 
potentially could be used for sequential treatment of patients. Previous treatment with 
bisphosphonates may blunt the effect of strontium ranelate on BMD for up to 6 months 
at the spine and for at least 12 months at other sites, according to a study in women with 
osteoporosis. After 6 and 12months of treatment with strontium ranelate, bisphospho-
nate- naive women (n = 56) had significant (p £ 0.002) increases in BMD at the spine 
(2.4% and 5.6%), total hip (1.9% and 3.4%) and heel (2.9% and 4.0%), whereas women 
previously treated with bisphosphonates (n = 52) had a significant (p = 0.002) increase 
in BMD only at the spine (2.1%) at the 12-month time point. The effect of strontium 
ranelate therapy on BMD at each of these sites was significantly (p < 0.05) more fa-
vourable in bisphosphonate-naive women than in those previously treated with bisphos-
phonates, at both the 6- and 12-month time point.. Strontium ranelate also produced im-
provements in the bone formation, microstructure and BMD of the fracture callus, com-
pared with no treatment. In women with osteoporosis, long-term (3 years) treatment 
with strontium ranelate 2 g/day did not adversely affect primary bone mineralization. 
Mineral apposition rate increased by 9% (p = 0.019) in cancellous bone and by 10% in 
cortical bone with strontium ranelate relative to placebo, as assessed by 2-dimensional 
histomorphometric analyses of bone biopsies. In another randomized, double-blind trial 
in 125 Asian women with osteoporosis, serum levels of bone ALP increased from base-
line with strontium ranelate 2 g/day and decreased slightly from baseline with placebo 
after 6 and 12 months of therapy, with significant (p £ 0.003) between-group differences 
being observed at both time points (15% and 26% at 6 and 12 months.  There was no 
significant between-group difference in the change from baseline in levels of CTX, 
which increased slightly from baseline with both strontium ranelate and placebo at 6 
and 12 months. The short-term effect of strontium ranelate on some biochemical mark-
ers of bone remodeling appears to be associated with long-term changes in BMD, but 
not fracture incidence, in women with postmenopausal osteoporosis, according to data 
from a post hoc pooled analysis (n = 2373) of two large clinical trial.  it has been sug-
gested that monitoring the clinical efficacy of strontium ranelate therapy with the use of 
markers of bone turnover in the individual patient may not be appropriate. The potential 
for strontium ranelate to be used in the treatment of postmenopausal osteoporosis was 
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established in a 2-year, randomized, double blind, placebo-controlled, multicentre, dose 
ranging (0.5–2mg/day) study (n = 353).  On the basis of the findings of this phase II tri-
al, a strontium ranelate dosage of 2 g/day was selected for further clinical evaluation 
The absorption of strontium is dose-dependent, but the increases in peak plasma con-
centration (Cmax) and the area under the concentration time curve (AUC) are less than 
dose-proportional over a dose range of 0.25–8 g, probably because of the saturation of 
an active absorption process. Following a single dose of strontium ranelate 2 g, the 
Cmax (»6mg/L) of strontium was reached in 3 hours, with steady state being achieved 
after 2 weeks of treatment. After an oral dose of strontium ranelate 2 g, the absolute 
bioavailability of strontium is »25% (range 19 27%). In postmenopausal women, stron-
tium has an accumulation ratio of »9 when the AUC from time 0 to 10 hours after the 
first dose was compared with that at steady state. Intake of calcium or food with stron-
tium ranelate administration reduces the bioavailability of strontium by »60–70% com-
pared with dose administration 3 hours after a meal.  Owing to the relatively slow ab-
sorption of strontium, food and calcium intake should be avoided for a period of time 
both before and after strontium ranelate administration. (Deeks, Dhillon, 2011) 
 
 
 
5.2.2.7 Calcitriol 
Calcitriol (1, 25-(OH) 2D3) is a hormone produced from VitD3 (Cholecalciferol). Sti-
mulates intestinal absorption of calcium and phosphate and mobilizes calcium and 
phosphate from hydroxyapatiteby stimulating bone resorption. These features enable 
restoration of blood levels of calcium and phosphate to normal when the two ions are 
low. It has been reported that 1, 25-(OH) 2D3 induces fusion and differentiation of ma-
crophages. An effect that has been interpreted to be the natural role of 1, 25-(OH)2D3 to 
induce osteoclastogenesis from the colony-forming unit for the granulocyte macrophage 
series in the bone marrow. It has been reported that although the osteoclast is the main 
bone-resorbing cell, it does not contain receptors for the main bone resorbing hormones, 
calcitriol and parathormon. In bone tissue, the anabolic effect of calcitriol is to increase 
the rate of mature osteoid production, and in the presence of normal blood calcium (Ca) 
and phosphate (PO4), this osteoid becomes mineralized. Histomorphometric studies of 
osteoporotic patients treated with calcitriol showed a similar increase in both osteoclasts 
and osteoblasts per surface. In a retrospective analysis of 26 osteoporotic women, Shi-
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raki and colleagues found that radial bone density increased in about half of the treated 
patients receiving 0.5 to 1.0 mg 1a-OH-D3 daily. Few randomized placebo-controlled 
trials of treatment of osteoporosis by calcitriol have addressed the clinically important 
issue of prevention of fractures. Tilyard and colleagues carried out a study in 622 wom-
en (50–79 years) over 3 years. The patients received either 0.25 mg calcitriol twice a 
day (314 patients) or 500 mg elemental calcium gluconate twice a day. Nearly 95% of 
the women treated with calcitriol were free of new fractures, compared with 80% of the 
calcium-treated group at the end of 3 years. Decline of fracture rate in patients under 
treatment with calcitriol was also found by other investigators. Thirty-seven patients (26 
females, 11 males, mean age66.4 years) with chronic obstructivepul monary disease un-
der treatment with corticosteroids for more than 2 years with 5–10 mg aprednisolone 
daily and osteopenia or osteoporosis confirmed by bone densitometry (lumbar spine or 
femoral. (Mirzaei, Zajicek, Knoll, et al 2003) 
 
5.2.3 New treatments approved by FDA 
 
5.2.3.1 Denosumab 
It is the most recent antiresorptive agent to be approved for the treatment of osteoporo-
sis. Denosumab is a monoclonal antibody against RANK-L. RANK-L stimulates the 
differentiation, activity and survival of osteoclasts, and is implicated in the pathogenesis 
of postmenopausal osteoporosis and other skeletal disorders associated with a high rate 
of bone remodeling. It has a potent action in slowing the rate of bone remodeling. The 
FREEDOM trial recruited 7868 postmenopausal women aged 60-90 years with a lum-
bar spine BMD T-score of less than -2.5 to -4.0 SD. Approximately 23% of the FREE-
DOM population had at least one prevalent vertebral fracture at the time of entry into 
the study.  Women were randomized to receive either denosumab 60 mg subcutaneously 
(n = 3902) or placebo (n = 3906) every 6 months. The primary end point was new ver-
tebral fractures at 3 years. The relative risk of vertebral fracture with denosumab was 
0.32 (95% CI 0.26, 0.41). New vertebral fractures occurred in 2% of women in the de-
nosumab group and in 7% of women in the placebo group.  After 3 years, the postme-
nopausal osteoporotic women receiving denosumab had a slightly reduced risk of hip 
fracture with a cumulative incidence of 0.7 per cent in the denosumab group versus 1% 
in the placebo group. (Reginster, 2011) 
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5.2.3.2 Lasofoxifene 
 
Evidence for lasofoxifene in the treatment of postmenopausal osteoporosis comes from 
the PEARL study. PEARL recruited 8556 women between the ages of 59 and 80 years 
with a BMD T-score of-2.5 SD or less at the lumbar spine; a prevalent vertebral fracture 
was not an entry requirement and only 28 per cent had at least one prevalent baseline 
radio graphically defined vertebral fracture. Women were randomized to lasofoxifene at 
a dose of either 0.25 or 0.5 mg/day or placebo. Only the results for the 0.5 mg/day dose 
were presented here because these were the marketed dose in Europe. The trial was 
planned to continue for 5 years; vertebral fracture was the primary endpoint for the first 
3 years of the trial. The hazard ratio for vertebral fracture with lasofoxifene 0.5 mg/day 
was 0.58 (95% CI 0.47, 0.70), indicating an RRR of 42 per cent. Lasofoxifene 0.5 
mg/day was associated with a reduction in the absolute incidence of radiography verte-
bral fractures at 3 years of 9.5 (13.5 vs 23 fractures per 1000 patient-years; 95% CI 5.2, 
13.7). The PEARL trial data allow calculation of relative and absolute risk over 5 years 
(but not 3 years). Therefore, the RRR for vertebral fracture over 5 years with lasofox-
ifene is 40 per cent, with an ARR of 4 per cent and an NNT of 26. In the same study, 
lasofoxifene failed to demonstrate a significant effect against hip fractures (hazard ratio 
0.77 95% CI 0.46, 1.27; not significant). (Reginster, 2011) 
 
6. METHODOLOGY  
 
This chapter deals with the methods of design study. This chapter deals with the me-
thods and design of the study. The study is a qualitative study in which the methods 
used in the entire study are literature review and content analysis. 
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Methodology is generally the guideline for solving problems with specific components 
such as phases, tasks, methods, techniques and tools. It is also the analysis of the prin-
ciple of methods, rules and postulates employed by a discipline.(Wikipedia) 
 
6.1 Qualitative analyses 
 
A method of inquiry employed in many different academic disciplines, traditionally in 
the social sciences but also in market research and further contexts. It produces informa-
tion on the particular cases studied and any more general conclusions are only proposi-
tions (informed assertions). It can be used to seek empirical support for such research 
hypotheses. (Wikipedia). Qualitative study broadly defined means any kind of research 
that produces findings not arrived at by means of statistical procedures or other means 
of quantification Sutcliffe. (Golafshani, 2003) 
In this study, qualitative research method was used in data collection where by the me-
thods used allowed the evaluator of this study to concentrate on the selected issues, cas-
es or events in depth and in details. 
 
6.2 Content analysis 
 
It is a methodology in the social sciences for studying the content of communication. It 
is summarizing, quantitative analysis of messages that relies on the scientific method 
and is not limited as to the types of variables that may be measured or the context in 
which the message are created or presented.(Wikipedia). Content analysis usually refers 
to analyzing text (interview, scripts, diaries, articles, journals, or documents) rather than 
observation-based field notes. More generally content analysis is used to refer to any 
qualitative data reduction and sense making effort that takes a volume of qualitative ma-
terial and attempts to identify core consistencies and meanings (Patton, 1990). 
The method used for this study was content analysis therefore author grouped the com-
mon themes that emerged from the findings into different categories which are as fol-
low: sub category, category and main category. The main idea was to analyze the find-
ings which intended to answer the research questions.  
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The articles that were collected from this study were selected carefully by the author 
and the previous researched articles considered in the study were those which were clin-
ical trials based on postmenopausal women and elderly men aged 65 and older. The 
credibility of previous articles used in this study was put into consideration which is the 
author, year of publication and the presentation of the findings. 
 
A systematic search was conducted through electronic databases EBSCO Host, Cinahl 
Ebsco and Google scholar for papers which were published from the year 2001-
2011.The search was conducted to review articles which had information on the phar-
macological treatment and non pharmacological treatment of osteoporosis in the elderly 
mostly the ones who are at the postmenopausal stage. The subject terms or keywords 
used were; Osteoporosis* postmenopausal* treatment* medicine research* or drugs* 
old age*or aging*.   
The data that was collected for the study was studied carefully by the author. The whole 
process was divided into 3 processes for the 3 categories. The main idea behind this was 
to group the data into sub groups and link the sub groups to main part which are the re-
search questions for the study. 
 
6.3 Study Outcome 
 
The study engulfs around the subject of osteoporosis in the elderly (65+), its prevention 
and the treatments already approved and available in the market. The aims and objec-
tives are achieved by the use of deductions from the previous research studies under li-
terature review through analyzing the findings 
6.4 Problems encountered 
 
The author encountered difficulties in obtaining articles and books that discussed con-
tent analyses and full text medical articles with clinical trials and books that discussed 
the current pharmacological treatments of osteoporosis. Most of the articles that were 
found were already reviewed by several other authors therefore the findings were not 
diverse. Another problem was that most of the current articles were not accessible freely 
so it was difficult to get the most current articles with the most current information.  
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However with the few articles that the author was able to access, the author was able to 
answer the two research questions posed for this study. 
 
6.5 Ethical Consideration 
 
Prior to writing the study the authors studied thoroughly and understood the Helsinki  
Declaration. The scientific published articles that were used as the basis for this study 
were reported in truth throughout the study. The author has fully and clearly docu-
mented all the sources for idea and words and texts that have been used in this study. 
References gotten directly from the articles and books used for this study have been 
quoted and written in inclusive of the authors name and the year of publishing. The au-
thor has fully documented sources for ideas and words used in the study 
 
6.6 Validity and Reliability 
Validity has been defined as truthfulness. Does the test measure what it purports to 
measure? It also refers to the extent to which certain inferences can be made from test 
scores or other measurement. (Mehrens, Lehman, 1987). It has also been defines as the 
degree to which they accomplish the purpose for which they are being used. (Worthen 
et al., 1993) 
Reliability has been defined as the degree of consistency between two measures of the 
same thing. (Mehrens, Lehman, 1987). 
 The measure of how stable, dependable, trustworthy, and consistent a test is in 
measuring the same thing each time (Worthen et al., 1993) 
Joppe (2000) defines reliability as: The extent to which results are consistent over time 
and an accurate representation of the total population under study is referred to as 
reliability and if the results of a study can be reproduced under a similar methodology, 
then the research instrument is considered to be reliable.  
The validity of a content analysis study refers to the correspondence of the categories to 
the conclusions, and generability of results to the theory. The validity of categories in 
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simplicity concept analysis in particular, is searched by utilizing multiple classifiers to 
arrive at an agreed upon definition of the category. In the study the author carefully 
studied the published articles that were chosen for this study. The results that were 
relevant and corresponding to the research questions were grouped into different 
categories as explained in the methodology part of this work.  
The published articles were retrieved from reliable databases that contain scientific 
research work done by professionals in the medical field. The results found in the study 
have all emerged from scientific articles that were used for this study and the author has 
not included any other sources in the results. The author has neither used past 
experiences nor the authors‟ knowledge to influence or alter the results. 
6. 7 Sample Process 
 
At the beginning of the search a trial was made to find data about elderly and osteoporo-
sis. The author used database EBSCO host to find the articles which were relative to the 
study. The subject terms were osteoporosis* risk factors* prevention* treatment* 
This search yielded 57905 hits. The author then conducted another search through 
EBSCO host database this time limiting the search to full text articles and this yielded 
2787 hits. The author was interested in the articles which were no older than ten years, 
so the search was restricted to the year 2001 to 2011, this yielded 1095 hits, the author 
also restricted the search to subject terms postmenopausal* elderly* (65 and older).The 
search yielded 37 hits. These articles were reviewed again this time taking into consid-
eration that the author was only interested in the articles that discussed current osteopo-
rosis risk factors and medication for osteoporosis prevention and treatment. The author 
came up with 7 hits which were found to be relevant to the study and produced clear 
information to the growth of the study. 
The author used CINAHL EBSCO search engine with the subject terms osteoporo-
sis*risk factors* prevention* treatment*elderly* the search produced 422 hits. The au-
thor further limited the search to the year 2001 to 2011. This search yielded 378 refer-
ences. The author was interested in the full text articles and the search yielded 27 hits. 
The 7 best articles were chosen. Another search using Google Scholar Advanced was 
conducted with the subject terms osteoporosis* risk factors* prevention* treatment* this 
yielded 487,000 hits. The author limited the search to timeline of 2001 to 2011 and also 
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to full text and this yielded yielded19 142 hits. The author was interested in the articles 
based on the menopausal elderly women and elderly men of age 65 and above and from 
those 4 best articles were chosen.  
The author ended up with 19 articles which were yielded by the search. The articles 
have been described in the table below 
 
Table 3. Summary of the articles used in the analyses  
Authors Articles 
 
Contents and Results 
 
DontasI.A, 
yiannakopolouous 
C.K(2007) 
 
Risk factor and pre-
vention of osteopo-
rosis related fractures 
 
The article is about Prevention of osteopo-
rosis and how it should ideally begin in 
childhood, aiming to achieve high peak 
bone mass accompanied by an inherently 
healthy lifestyle throughout life, in order 
to minimize bone loss during middle and 
third age, and in parallel to avoid or di-
minish other fracture risk factors 
 
Tauseef 
Chaudhri(2006) 
Identifying nutri-
tional and lifestyle 
risk factors associ-
ated with the devel-
opment of osteopo-
rosis in women of 
Asian origin 
The objective of this study was to identify 
the risk factors associated with the occur-
ence of osteoporosis in Kenyan A sian 
women seen in Agah Khan University 
Hospital, Nairobi Kenya and the findings 
were that the risk factors were identified 
were age, waist size, hip size, BMI, low 
physical activity, and use of prescription 
drugs. 
Spangler , et al(2011) Calcium supplemen-
taion in postmeno-
pausal women to re-
duce the risk of os-
teoporotic fractures 
The purpose of this article was to evaluate 
the effects of calcium supplementation for 
prevention of osteoporosis-related frac-
tures in postmenopausal women and the 
results indicated that calcium supplemen-
tation does not significantly reduce frac-
ture risk in postmenopausal women. And 
evidence from the same studies suggests 
that beneficial effects on fracture risk may 
be seen in women who are adherent to 
therapy and Postmenopausal women 
should continue calcium supplementation 
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to reduce osteoporosis risk. 
Mac Laughlin, Eric. J, 
RaehlCynthia L(2008) 
ASHP Therapeutics 
position statement on 
the prevention and 
treatment of osteopo-
rosis in Adults 
The article is a review on prevention and 
treatment of osteoporosis in Adults. The 
author encourages that health care profes-
sional to educate patients about risk fac-
tors associated with osteoporosis. They 
further encourages health care profession-
als to identify and triage at risk patients 
for osteoporosis screening and diagnosis 
.  
JunIwamoto, Yoshi-
hiro,et al (2008) 
Hip fracture protec-
tion by alendronate 
treatment in post-
menopausal women 
with osteoporosis 
The purpose of this paper was to discuss 
the efficacy of alendronate against hip 
fractures and the mechanism for this anti-
fracture efficacy in postmenopausal wom-
en with osteoporosis results states that 
alendronate strongly suppresses bone 
turnover and subsequently increases hip 
BMD, decreases cortical porosity, im-
proves parameters of hip structure, and 
produces more uniform in cortical bone. A 
once-weekly regimen of alendronate ad-
ministration provides better patient com-
pliance and persistence with the treatment 
than the once-daily dosing regimen, lead-
ing to greater efficacy against hip frac-
tures. Thus, the efficacy of alendronate 
against hip fractures has been confirmed 
in postmenopausal women with osteopo-
rosis, especially with a once-weekly dos-
ing regimen. 
S.Boonen, 
Vanderschueren et al 
(2006) 
Osteoporosis man-
agement a prospec-
tive based on 
biosphosphonates 
data methods 
This article describes the evidence base 
that supports. The types of individuals 
who should receive calcium and vitamin 
D supplements are those patients with 
documented osteoporosis receiving antire-
sorptive or anabolic treatment, patients 
receiving glucocorticoids and individuals 
with or at high risk of calcium and/or vi-
tamin D insufficiencies, in particular older 
women and men. The results on evidence 
have shown that. Calcium and vitamin D 
supplementation is most effective when 
targeted to those who are receiving antire-
sorptive or anabolic osteoporosis Therapy, 
are being treated with glucocorticoids and 
are likely to be calcium or vitamin D in-
sufficient. 
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RahmaniPoupak, 
Morin Suzanne (2009) 
Prevention of osteo-
porosis related frac-
tures among post-
menopausal women 
and older men 
This article addresses the approach to 
managing osteoporosis in postmenopausal 
women and older men. The findings were 
that Pharmacologic agents for the treat-
ment of osteoporosis are effective in pre-
venting fractures in postmenopausal 
women and elderly men at high risk (10-
year absolute risk of any osteoporosis-
related fracture > 20%). 
Deutschmann H.et al 
(2002) 
Impact of identified 
possible risk factors 
on bone mineral den-
sity 
The article was to determine whether the 
use of more elaborate diagnostic tests can 
identify possible risk factors for secondary 
osteoporosis and to evaluate the impact of 
these possible risk factors on the severity 
of bone disease in the study population. 
Findings were that one or more possible 
risk factors for osteoporosis were re-
vealed. The most common were lactose 
malabsorption, disturbed exocrine pan-
creatic function and renal tubular distur-
bances, including renal hypercalciuria, 
incomplete renal tubular acidosis and mild 
phosphate diabetes  
Bito C. M Moran, 
Bastistella L. R(2005) 
Effects of alendro-
nate on bone mineral 
density in spinal cord 
injury patients 
The aim of the article was to evaluate the 
effect of alendronate on bone mineral 
density in chronic spinal cord injury (SCI) 
patients. Findings were that the use of 
alendronate had a positive effect on bone 
mineral density in SCI patients and there-
fore represents a potential tool for preven-
tion and treatment of osteoporosis in this 
population. 
Deane Andrew et al 
(2007) 
The impact of Vita-
min D status on 
changes in bone min-
eral  density during 
treatment with 
bisphosphonates and 
after discontinuation 
following long term 
use in postmeno-
pausal  osteoporosis 
The aim was to assess the impact of vita-
min D status on changes in bone mineral 
density (BMD) in firstly patients with 
post-menopausal osteoporosis on bisphos-
phonates and secondly following discon-
tinuation of bisphosphonates after long-
term use. Findings were that optimal se-
rum 25 (OH) vitamin D concentration 
may lead to further reduction in bone loss 
at the hip in patients on bisphosphonates 
Recker R, et al (2005) Treatment of early 
postmenopausal 
womenwith 
bisphosphonates 
The articles talks about bisphosphonates 
as being the most commonly prescribed 
therapy for the prevention and treatment 
of osteoporosis and affect bone formation, 
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 primarily through a reduction of activation 
frequency and increases in secondary mi-
neralisation. 
Cadarette Suzanne et 
al (2008) 
Relativeeffectiveness 
of osteoporosis drugs 
for preventing non 
vertebral fractures 
The aim of the article was to compare the 
relative effectiveness of osteoporosis 
treatments to reduce nonvertebral fracture 
risk among older adults. Findings were 
that differences in fracture risk between 
risedronate or raloxifene and alendronate 
were small. Nasal calcitonin recipients 
may have a higher risk for nonvertebral 
fractures compared with alendronate reci-
pients 
Black M.D, Delmas P. 
D, et al (2007) 
Once-yearly 
zolendronic acid for 
treatment of 
postmenopausal 
osteoporosis 
The aim was to assess the effects of an-
nual infusions of zoledronic acid on frac-
ture risk during a 3-year period. Treatment 
with zoledronic acid reduced the risk of 
morphometric vertebral fracture by 70% 
during a 3-year period 
Lyes K.W,et al (2007) Zolendronic acid in 
reducing clinical 
fractur and mortality 
after hip fracture 
The aim was to determine the effects of 
zoledronic acid on clinical fractures and 
mortality after hip fracture. Findings were 
that an annual infusion of zoledronic acid 
within 90 days after repair of a low-
trauma hip fracture was associated with a 
reduction in the rate of new clinical frac-
tures and with improved survival 
Chesnut Charles H 
(2006) 
The role of salmon 
calcitonin in the 
treatment of vertebral 
fractures 
The article was to determine the role of 
salmon calcitonin in the treatment of ver-
tebral fractures. Findings indicated that 
the mechanism of action for salmon calci-
tonin nasal spray appears to be less related 
to an increase in BMD, but rather to its 
inhibition of bone resorption and to the 
preservation of bone micro architecture. 
VermaatHester, 
KirtschigGudula 
(2008) 
Prevention and 
treatment of gluco-
corticoid induced 
osteoporosis in daily 
dermatologic prac-
tice 
The aim of the article was to  provide an 
update of the recent advances in the pre-
vention of GIO in dermatologic practice. 
Findings were that prophylaxis of osteo-
porosis needs to be started early during 
treatment with GCs. Calcium and vitamin 
D supplements in all patients on systemic 
GCs and bisphosphonates in patients who 
take GCs for more than 3 months are 
practical and effective measures 
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7. PRESENTATION OF RESULTS 
This chapter consists of the results that were found in this study.  The results have been 
divided into 3 parts according to the three research questions. 
Question 1. What are the current risk factors for osteoporosis in the elderly and how 
they can be controlled? 
Most modifiable risk factors directly impact bone biology and result in a decrease in 
bone mineral density (BMD), but some of them also increase the risk of fracture inde-
pendently of their effect on bone.. Although fixed risk factors cannot be changed, 
people need to be aware of them so that they can take steps to reduce bone mineral loss 
 
Mauck Karen. F, 
Clarke Bartl I (2006) 
Diagnosis, screening, 
prevention and 
treatment of osteopo-
rosis 
The purpose of the article was to provide 
overview of the diagnosis, screening, pre-
vention, and treatment of osteoporosis. It 
states that clinicians need to be vigilant in 
instituting primary prevention measures 
for those at high risk for osteoporosis and 
in instituting treatment for patients diag-
nosed as having the disease either by 
screening or a history of fracture 
Michael Kane, Abu 
Baker (2008) 
Teriparatide in the 
treatment of osteopo-
rosis 
The purpose was to review the efficacy, 
safety, and cost of teriparatide in the 
treatment of osteoporosis. Findings were 
that teriparatide offers a therapeutic option 
for patients at high risk of an osteoporotic 
fracture and for patients who are intole-
rant of or unresponsive to antiresorptive 
therapy. 
Deeks Emma, Dhil-
lion Sohita (2010) 
The effects of PTH 
or strontium ranelate 
on bone formation 
markers in post-
menopausal women 
with primary osteo-
porosis 
Aim was to explore the effects of PTH 
compared with strontium ranelate on bone 
remodelling as measured by bone remod-
elling markers in postmenopausal women 
with osteoporosis. Findings: PTH had a 
more rapid and higher effect on bone for-
mation markers compared to SR, indicat-
ing  that SR has a different mode of action 
on bone remodelling than the bone build-
ing agent PTH in postmenopausal women 
with osteoporosis 
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SUB-CATEGORY                           CATEGORY                     MAIN-CATEGORY 
Inadequate exercise, in-
adequate nutrition, Cal-
cium and vitamin D defi-
ciency, smoking, alcohol 
abuse, certain drugs and 
medications and life 
styles, low body weight 
 
Can be controlled 
Current risk factors for 
osteoporosis in the elderly 
 
 
SUB-CATEGORY                            CATEGORY                       MAIN-CATEGOEY 
Age, gender, race, early 
menopause, family history. 
 
Cannot be controlled 
 
Current risk factors for 
osteoporosis in the elderly 
 
 
 
 
Question 2. What are the classifications of osteoporosis medications and their effects 
on the disease? 
From this study, it has clearly shown that osteoporosis medications are classified and 
categorized in different classes and have different purposes. This categorization have 
clearly helped to answer the second question of this study 
SUB-CATEGORY                        CATEGORY                       MAIN-CATEGORY 
Alendronate 
Risedronate 
Ibandronate 
Raloxefine 
Denosumb 
Strontium ranelate 
 
Calcitriol  
Bisphosphonate 
 
 
Selective estrogen receptor modulator 
Miscellaneous bone resorption inhibitor 
Dual acting bone agent 
 
Parathyroid hormone and analogs                           
                
 Treatment and Prevention 
 
 
 
SUB-CATEGORY                  CATEGORY                              MAIN-CATEGORY 
Teriparatide Parathyroid hormone and analogs Treatment 
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Calcitonin 
Zolendronate 
Calcitonin 
Bisphosphonate 
 
 
SUB-CATEGORY                  CATEGORY                              MAIN-CATEGORY 
Estrogen 
Calcium & Vitamin D 
Hormone Replacement Therapy 
Vitamin and mineral combination   
Prevention 
 
Question 3. What are the current approved medications for osteoporosis and their me-
thods of administration? 
This study has also found that Food and Drug Administration (FDA) have already ap-
proved several medications to the treatment of osteoporosis and their methods of admin-
istration in the elderly. These approved medications are classified into categories in 
which answers the third research question of this study. 
MAIN CATEGORY                    SUB-CATEGORY                    CATEGORY 
Bisphosphonate 
 
 
 
Dual acting bone agent 
Monoclonal antibody 
Selective  oestrogen receptor 
Parathyroid hormone & analogs  
Alendronate 
 
Risendronate 
Ibandronate 
Strontium ranelate 
Denosumab 
Raloxifene 
Calcitriol  
 
P: 5 mg Daily, 35 mg Weekly tablet 
T: 10 mg Daily, 70 mg weekly tablet 
P,T: 5 mg Daily, 5 mg, 35 mg weekly tablet 
P,T  2.5 mg Daily, 150 mg Monthly tablet/3 IV 
P,T:2 g Daily soluble sachet(2 Months) 
P,T: 60 mg Six months subcutaneous IV 
P,T: 60 mg Daily tablet   
P.T: 0 .5 to 1.0 mg Daily (1a-OH-D3) 
 
MAIN CATEGORY                   SUB-CATEGORY                     CATEGORY 
Vitamin& Mineral  
Hormone replacement therapy 
Calcium & Vitamin D   
  Estrogen 
P: 1200mg Ca & 1200 IU Vi  Daily tablets 
P: 0.625 (CEE) Daily Formula 
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MAIN CATEGORY                          SUB-CATEGORY                CATEGORY 
Bisphosphonate 
Calcitonin 
Parathyroid hormone & analogs 
Zolendronate 
Calcitonin 
Teriparatide 
T: 5 mg Annual IV infusion 
T: 200µ Daily nostril spray 
T: 20/ig Daily injection 
.  
 
Greater choices of therapies with potentially fewer side effects are now available. Frac-
ture risk can be reduced by 40 to 60 per cent by identification of osteoporosis and use of 
osteoporosis medications in the elderly. Individual drugs may have contraindications 
and potential side effects and will not suit all patients.  
Alendronate, risedronate, denosumab, strontium ranelate and zoledronate have an evi-
dence base for the reduction of fractures. Alendronate, teriparatide and zoledronate are 
approved for the prevention and treatment of corticosteroid-induced osteoporosis in men 
and women. Risedronate is approved for the prevention and treatment of corticosteroid-
induced osteoporosis in postmenopausal women. Other approved pharmacological in-
terventions for postmenopausal women include calcitonin, calcitriol and hormone re-
placement therapy (HRT).  
Generic bisphosphonate is usually the first choice of therapy, partially because of its 
low cost and long-term base of clinical trial data. Patients with abnormalities of the eso-
phagus are not suitable for bisphosphonate treatment and those who develop swallowing 
problems or pain behind the sternum are advised to stop treatment and consult their pre-
scriber. Other therapies, such as risedronate, denosumab or strontium ranelate may be 
required in women (Elliott, 2011) 
. 
International guidelines agree that agents that have been shown to decrease vertebral, 
nonvertebral and hip fractures should be used preferentially over agents that only dem-
onstrate vertebral antifracture efficacy. This is the case for alendronate, risedronate, zo-
ledronic acid, and denosumab and strontium ranelate 
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7.1 Alendronate 
Alendronate 70mg administered once weekly and 35mg twice weekly are as effective at 
increasing BMD as 10 mg/day in the patient group. Absorption and disposition of alen-
dronate over the dosage range 5 to 80mg are linear. Beverages (other than water), food 
and calcium supplements all reduce absorption of alendronate. The drug is either ex-
creted by the kidneys, the only route of elimination, or taken up and sequestered by 
bone, from where it is slowly released. The mean steady-state volume of distribution of 
alendronate, excluding bone, is estimated to be at least 28L. (Sharpe, Noble,  et al 
2001). Alendronate is also a suitable treatment option for primary osteoporosis in men 
and for corticosteroid-induced osteoporosis in both men and women. (Miriam Sharpe, 
Stuart Noble et al 2001).  The use of alendronate had a positive effect on bone mineral 
density in SCI patients and therefore represents a potential tool for prevention and 
treatment of osteoporosis in this population. (Brito, Battistella, 2005).  
 
7.2 Risedronate 
Retrospective analyses showed that risedronate significantly reduced the incidence of 
nonvertebral and clinical vertebral fractures within 6 months. Treatment with risedro-
nate for 36 months reduced the risk of vertebral fractures by 41 per cent and non verte-
bral fractures by 39 per cent relative to placebo in women with at least one existing ver-
tebral fracture17 and the risk of hip fractures by 40 per cent relative to placebo in wom-
en aged 70 to 79 with osteoporosis. (Boonen, et al, 2010). Results from observational 
studies suggest that risedronate may reduce the risk for nonvertebral fracture (clavicle, 
hip, humerus, leg, pelvis, and wrist) within 12 months more effectively than alendronate 
or nasal calcitonin (Cadarette, et al 2008) 
  
7.3 Zoledronic acid 
The incidence of any clinical fracture, clinical vertebral, or nonvertebral fracture in 
postmenopausal women aged 75 and older was significantly lower in the ZOL group 
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than in the placebo group over 3 years (P<.001, P<.001, and P=.002, respectively) in 
HORIZON trial. A similar finding has been shown for any clinical fracture and clinical 
vertebral fractures at 1 year (P=.03 and P=.009, respectively), but the incidence of non-
vertebral fracture at 1 year and hip fracture at 1 and 3 years was lower for the ZOL 
group although not significantly (Black, et al, 2007). In another trial that involved men 
and women with a recent hip fracture.  Zoledronic acid was also found to decrease mor-
tality by 28 percent compared with placebo in the study involving patients with a recent 
hip fracture (number needed to treat = 29). (Lyles, et al, 2007) 
 
7.4 Ibandronate 
Intermittent ibandronate extends the range of pharmacological therapies for the treat-
ment and prevention of postmenopausal osteoporosis. It inhibits osteoclast-mediated 
bone resorption. In clinical trials in postmenopausal women with osteoporosis, approved 
oral and intravenous ibandronate dosage regimens reduced bone turnover, and increased 
lumbar spine and proximal femur bone mineral density (BMD) and mechanical strength. 
(Frampton, Perry, 2008). Preclinical studies initially revealed the feasibility of extend-
ing the between-dose interval. Subsequent clinical studies have provided further evi-
dence of the positive effects of extended-interval ibandronate administration in reducing 
the risk of vertebral fractures through increasing bone mineral density and reducing 
bone turnover without compromising bone quality. (Chestnut, 2006).  The once daily 
oral formulation of ibandronate is not commercially available. Patients prescribed once 
monthly oral ibandronate should take their tablet preferably on the same date each 
month and after an overnight fast (6 hours or more) and /or 1 hour or more before the 
first food and drink of the day or any other oral medication or supplement. The tablet 
should be taken with plain water while sitting or standing in an upright position and pa-
tients should not lie down for 1 hour afterwards.  ( Frampton, Perry, 2008).  
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7.5 Raloxifene 
Raloxifene was the first SERM approved for the prevention and treatment of osteoporo-
sis in postmenopausal women. In the MORE study, the relative risk of vertebral fracture 
with raloxifene was 0.70 (95% CI 0.6, 0.9). New vertebral fractures occurred in 113 
(15%) women in the raloxifene group and in 163 (21%) women in the placebo group. In 
a meta-analysis of 7 trials in which postmenopausal women were given raloxifene or 
placebo, raloxifene was associated with a risk reduction in vertebral fractures (RR 0.60, 
95% CI 0.50–0.70; number needed to treat = 2381 to 99 across the range of fracture risk 
for 2 years of treatment).There was little effect of raloxifene on the risk of other frac-
tures. (Cranney. et al.2002, Connor, et al, 2006).   
 
7.6 Calcitonin 
Calcitonin is very useful in the acute management of vertebral fractures where it ap-
pears to confer analgesic properties, leading to a reduction in pain within two weeks 
with subsequent improvement in mobility (Sutcliffe 2005). By evaluating the efficacy of 
calcitonin for the treatment and prevention of GIO in a meta-analysis, the results 
showed that calcitonin prevented bone loss at the spine and forearm by about 3 percent 
after the first year of therapy. The American Committee of Rheumatology, for example, 
considers calcitonin as a second-line agent in patients with a low BMD who cannot tole-
rate bisphosphonates (Vermaat, Kirtschig, 2008).In the ability to prevent future verte-
bral fractures, salmon calcitonin also appears to possess analgesic activity so this agent 
may be useful in the treatment of acute vertebral fractures, in which back pain can be 
significant (Mac Laughlin, Raehl 2008) 
 
7.7 Estrogen / Hormone therapy 
Findings from the Women's trials performed in the United States (US) have shown 
beneficial effects of continuous combined oestrogen and progestogen on fracture out-
comes. On the basis of these findings HRT is no longer recommended as a long-term 
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therapy for the prevention of bone loss or treatment of established disease in the older 
woman (Anne Sutcliffe 2005). Strong consideration of other medications that have been 
shown to decrease the risk fractures and weighing of the risks and benefits are recom-
mended before using estrogen solely to prevent osteoporosis. (Mac Laughlin, Raehl 
2008)‟ 
 
7.8 Teriparatide. 
Teriparatide use should be avoided in patients at increased baseline risk for osteosarco-
ma, such as patients with Paget‟s disease. Teriparatide should not be used for more than 
two years because safety and efficacy for longer periods have not been evaluated. Since 
the commercial launch of teriparatide in December 2002, a worldwide safety monitoring 
program has identified one confirmed case of osteosarcoma in a patient treated with te-
riparatide. Lundkvist et al reported that teriparatide monotherapy is cost-effective if 
used in women who are 69 years or older, have femoral neck T-scores of –3.0 or worse, 
and have a history of a vertebral fracture. Appropriate candidates for teriparatide thera-
py include men and women at high risk of an osteoporotic fracture, patients unable to 
tolerate antiresorptive therapy, and patients who have worsening BMD or who suffer a 
fracture while receiving antiresorptive therapy. . Prospective studies are needed to as-
sess teriparatide‟s ability to reduce rates of hip and wrist fractures. Data are also needed 
to verify teriparatide‟s long-term safety (Stroup, et al, 2008) 
 
7.9 Strontium Ranelate 
This is used in women with osteoporosis, in whom long-term treatment with strontium 
ranelate was shown to improve bone microarchitecture, which may, in turn, improve 
bone biomechanical competence and explain the antifracture efficacy of strontium rane-
late. In a small prospective cohort study, strontium ranelate 2 g/day for 12 months was 
shown to increase (p = 0.033) lumbar spine BMD (and reduce bone markers to baseline 
levels.  In 19 (evaluable) women with postmenopausal osteoporosis who had previously 
been treated with teriparatide 20 mg/day for 18 months and had experienced a signifi-
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cant (p < 0.001) increase in BMD during this period, suggesting that strontium ranelate 
potentially could be used for sequential treatment of patients. The potential for stron-
tium ranelate to be used in the treatment of postmenopausal osteoporosis was estab-
lished in a 2-year, randomized, double blind, placebo-controlled, multicentre, dose rang-
ing (0.5–2mg/day) study (n = 353). (Deeks, Dhillon, 2011) 
 
7.10 Calcitriol 
Histomorphometric studies of osteoporotic patients treated with calcitriol showed a sim-
ilar increase in both osteoclasts and osteoblasts per surface. Few randomized placebo-
controlled trials of treatment of osteoporosis by calcitriol have addressed the clinically 
important issue of prevention of fractures. Patients received either 0.25 mg calcitriol 
twice a day, (314 patients) or 500 mg elemental calcium gluconate twice a day. Nearly 
95 per cent of the women treated with calcitriol were free of new fractures, compared 
with 80 per cent of the calcium-treated group at the end of 3 years. Decline of fracture 
rate in patients under treatment with calcitriol was also found by other investigators. ( 
Mirzaei, et al, 2003) 
 
7.11 Denosumab, Lasofoxifene 
These are most recent approved drugs by the FDA. Denosumab has a potent action in 
slowing the rate of bone remodeling. In the FREEDOM trial. After 3 years, the postme-
nopausal osteoporotic women receiving denosumab had a slightly reduced risk of hip 
fracture with a cumulative incidence of 0.7 per cent in the denosumab group versus 1 
per cent in the placebo group, giving an ARR of 0.3 per cent and an NNT of 
334.(Reginster 2011) 
Lasofoxifene 0.5 mg/day was associated with a reduction in the absolute incidence of 
radiography vertebral fractures at 3 years of 9.5 (13.5 vs. 23 fractures per 1000 patient-
years; 95% CI 5.2, 13.7). I n the PEARL study, lasofoxifene failed to demonstrate a sig-
nificant effect against hip fractures (hazard ratio 0.77 95% CI 0.46, 1.27; not signifi-
cant). (Reginster 2011) 
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8.  DISCUSSION, CONCLUSION AND RECOMMENDATIONS 
Osteoporosis is a largely treatable condition and with a combination of lifestyle changes 
and appropriate medical treatment, many fractures can be avoided. Osteoporotic frac-
tures are a cost in terms of morbidity and mortality for older people and financially for 
the health economy. Identification of high-risk patients and the provision of interven-
tions are important steps in the prevention of fractures and resultant frailty. New and 
emerging medicines and approaches offer a wider choice of treatment options. 
 
Pharmacologic agents for the treatment of osteoporosis are effective in preventing frac-
tures in postmenopausal women and elderly men at high risk (10-year absolute risk of 
any osteoporosis-related fracture > 20%). All of the proposed interventions are cost-
effective compared with no treatment in postmenopausal women. The gains associated 
with each intervention are strongly related to the age of the patient, the presence of frac-
ture and the agent used. Practice guidelines recommend pharmacologic intervention in 
men and women who have had a fragility fracture and whose T scores is −1.5 or lower.. 
( Rahmani, Morin,  2009) 
 
 
Selecting the most appropriate agent for an individual patient requires the assessment of 
the relative value of a particular intervention overall other relevant interventions of 
choice. With recent additions to the therapeutic armamentarium, physicians now have at 
their disposal a wide range of osteoporosis treatments. On the other hand, randomized 
controlled trials are often designed for registration purposes and only include a placebo 
comparison or one active comparator. Head-to-head comparisons of all available agents 
are unlikely to become available because of the prohibitive costs and sample size that 
such a study would require. As a result, information on the efficacy of osteoporotic 
treatments relative to one another remains limited. (Reginster 2011) 
 
Oral bisphosphonate therapy is considered first-line therapy in the management of os-
teoporosis. Not all agents are covered by drug benefit formularies, therefore clinicians 
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should determine which ones are covered in their own setting. Measurement of bone 
mineral density should be repeated 2 years after initiating treatment to monitor the ef-
fectiveness of treatment 
 
Randomized controlled trials provide solid evidence that the bisphosphonates, the 
SERMs, denosumab, teriparatide and strontium ranelate prevent vertebral fractures 
compared with placebo. There is also sound evidence for the prevention of hip fracture 
with alendronate, risedronate, zoledronic acid, and denosumab and strontium ranelate. 
No single agent is appropriate for all patients and therefore treatment decisions should 
be made on an individual basis, taking into account all measures of treatment effect and 
the patient's baseline risk before making informed judgments about the best individual 
treatment  
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